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INTRODUCTION 
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The genus Enterococcus consists of Gram-positive, facultatively anaerobic 
organisms that are spectacle shaped and may appear on smear in short chains, in 
pairs or as single cells. Enterococci, though commensals in adult feces are 
essential nosocomial pathogens.  
Enterococcal infections may of at least 12 species 
including Enterococcus faecalis, E. faecium,E. durans, E. avium, E. casseliflavu
s, E. gallinarum, E. hirae, E.malodoratus, E. mundtii, E. pseudoavium, E. raffin
osus, and E. solitarius. Among enterococcal species,  E.faecalis and  
E. faecium  are the two major human pathogens accounting for 85-89% and 10-
15% of all enterococcal infections, respectively.  
Prior to the 1990s also, enterococci have been recognized as an important cause 
of bacterial endocarditis for almost a century. However, recently they are 
recognized as a cause of nosocomial infection and "superinfection" in patients 
receiving antimicrobial agents. The most common Enterococci-associated 
nosocomial infections are of the urinary tract, followed by surgical site 
infections and bacteremia. 
The intrinsic antibiotic resistance pattern of Enterococci, along with their 
promiscuity in acquisition and dissemination of genetically versatile antibiotic 
resistance elements, presents serious challenges to the treatment of enterococcal 
infections. Infections by Enterococci have traditionally been treated with cell 
wall active agents (e.g., penicillin or ampicillin) in combination with an 
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aminoglycoside (streptomycin/gentamicin), More ever, emergence of high level 
aminoglycoside resistance (HLAR), 𝛽 lactam antibiotics and to vancomycin by 
some strains has led to failure of synergistic effects of combination therapy.  
Vancomycin is an effective antimicrobial for treating infection caused by gram 
positive organisms. Gram positive isolates are often routinely tested for 
vancomycin susceptibility. In the 1970s, hospital-associated enterococcal 
infections in the United States were mainly due to E.faecalis. More recently, 
E.faecium has emerged as therapeutically challenging organism because of its 
resistanceto vancomycin and pencillin. These VRE  isolates also have a high 
level of resistance to aminoglycosides  Resistance to glycopeptides is mediated 
by alteration of the drug target from D-alanine-D-alanine to D-alanine-D-
lactate. So far, eight genotypes of glycopeptide resistance, which are different in 
the level and range of resistance and in transfrability of glycopeptides, have 
been described for enterococci. Five of the van genes are acquired (van A , B , 
D , E , G) and three (vanC1,C2,C3) are intrinsic. Multiple epidemics have been 
predominantly reported with vanA type . vanA gene cluster is located within 
transposon Tn1546 and can be transferred through acquired resistance. 
The CLSI recommends screening of enterococci for high level aminoglycoside 
resistance with both gentamicin and streptomycin isolated from blood cultures 
or specimens such as heart valve tissue. The emergence of multidrug resistant 
Enterococci, especially Vancomycin Resistant Enterococci (VRE), and its 
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spread has caused the occurrence of many hospital Out breaks worldwide. In the 
United States, vancomycin-resistance Enterococcus faecium accounted for 4 per 
cent of healthcare-asssociated infections. It is the second most common 
pathogen causing mortality and morbidity and the 3rd leading cause of hospital 
acquired blood stream infection.   
The prevalence in Asian countries is decreased and  probably due to recent 
emergence of this resistance in this continent and only a handful of studies to 
document. In India, the prevalence of VRE has been reported as 8%, 5.5% and 
23% in New Delhi, Chandigarh, and Mumbai, respectively, all of vanB 
phenotype.  
Enterococci have emerged as the leading causes of Multiple drug resistant 
hospital-acquired pathogens especially with the emergence of glycopeptide-
resistant enterococcus (GRE) species. 
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REVIEW OF LITERATURE 
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DESCRIPTION OF GENUS: 
Enterococcus was historically termed as a diverse genus identified as being 
'faecal streptococci', associated with the gastrointestinal tract of human (Giraffa 
2002).  Thiercelin in 1899 first coined the term 'enterocoque' to describe a 
newly found Gram-positive diplococcus species. 
Andrews and Horder in 1906, isolated the same organism from an endocarditis 
patient and named it 'Streptococcus faecalis' (Murray 1990). Based on antigens 
identified as being group-specific, enterococci were placed in Streptococcus 
group D, while pyogenic streptococci belong to groups A, B, C, E, F or G using 
antisera. Enterococci were thus classified as group D streptococci because of 
their morphology and Lancefield antigenicity.  
The antigenicity of the carbohydrate moiety of the cell wall is designated 
according to a system devised by Lancefield in the 1930s (Smith, Niven et al. 
1938). The established lance field antigen of Streptococcus is a virulence 
determinant. For example, in group A streptococci it plays a significant role in 
resistance to platelet-derived antimicrobials in serum, neutrophil killing and the 
cathelicidin antimicrobial peptide LL-37 (van Sorge, Cole et al. 2014). 
Many efforts have been made to classify these organisms into better taxonomic 
groups due to their great diversity. A new classification pattern was proposed by 
Sherman in 1937 that classified streptococci into four main groups which are 
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pyogenic, viridans, lactic streptococci and enterococci. In 1984 research carried 
out using nucleic acid hybridization revealed the latter 
group showed only meagre association to streptococci (Sherman, Mauer et 
al.1937).  
Subsequently based on molecular techniques, DNA hybridisation,DNA: rRNA 
hybridisation and 16S rRNA sequencing revealed that S.faecalis and S. faecium 
were only distantly related to other streptococci. 
The new genus named Enterococcus was proposed and S. faecalis and 
S.faecium were removed from the genus Streptococcus and renamed as 
Enterococcus faecalis and Enterococcus faecium, respectively 
(Schleifer,Kilpper-Balz et al. 1984, Ludwig, Seewaldt et al. 1985). The 
classification of enterococci has been challenging because it is a heterogeneous 
group of Gram-positive cocci which is more closely related to the genera 
Carnobacterium, Lactococcus and Vagococcus, but still has many 
characteristics of the genus Streptococcus (Leclerc, Devriese et al. 1996). 
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The genus of Enterococcus is composed of more than forty species (The 
National Center for Biotechnology Information, NCBI), classified on the basis 
of pigment production, motility and ability to generate acids from a range of 
carbohydrates (Fischetti, Novick et al. 2006).  
Based on the chemotaxonomic and phylogenetic studies, the establishment of 
16S rRNA sequences led to the description of seven clonal complexes within 
the genus namely             (i) E. faecalis, E. haemoperoxidus and E. moraviensis; 
(ii) E.faecium, E. durans, E. hirae, E. mundtii, E. pocinus, and E. villorum; (iii) 
E.avium, E. pseudoavium, E. malodoratus, and E. raffinosus; (iv) 
E.casseliflavus, E. gallinarum and E. flavescens; (v) E. cecorum and 
E.columbae; (vi) E. dispar and E. asini; (vii) E. saccharolyticus and 
Domain: Bacteria 
Division: Firmicutes 
Class: Bacilli 
Order: Lactobacillales 
Family: Enterococcaceae 
Genus: Enterococcus 
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E.sulfureus. Other species are E. gilvus, E. pallens and E. ratti (Klein 2003) 
While there are multiple species in the genus Enterococcus, two are associated 
with the majority of human infections, E. faecalis and E. Faecium (Magi, 
Capretti et al. 2003). 
Characteristics of Enterococci: 
 The enterococci are gram-positive cocci typically arranged in pairs and short 
chains, non-motile and non-capsulate. The cocci are facultative anaerobes and 
grow optimally at 35°C, although most isolates can grow in the temperature 
range l0ºC to 45°C. They grow readily on blood agar , with large, white 
colonies appearing after 24 hours of incubation; the colonies are typically non-
hemolytic but can be ∝-hemolytic or 𝛽 -hemolytic. It grows readily on ordinary 
nutrient media and on MacConkey agar, on which it forms small (0.5-1 mm), 
usually magenta-colored colonies. 
 
Distinctive Features of Enterococci: 
The Enterococci possess several distinctive features separating them from 
streptocooci: The enterococci grow in the presence of 6.5 percent NaCl, 40 
percent bile, at pH 9.6, at 45°C and in 0.1 percent methylene blue. It survives 
heating at 60°C for 30 min, a feature distinguishing it from streptococci, and 
also grows within a wider range of temperatures (10-45°C). On MacConkey 
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medium they produce deep pink colonies. Enterococci are PYRase test positive. 
They do not hydrolyze hippurate. 
 
Enterococcal Species:  
The genus was established in 1984 with the characterization of Enterococcus 
faecalis and Enterococcus faecium; however, a further 32 species have now 
been added to the genus on the basis of chemotaxonomic and phylogenetic 
studies. These additions were based on evidence provided by 16S rRNA 
sequencing studies. 
 
E. faecalis                                    Schleifer and Kilpper-Balz 1984 
E. faecium                                    Schleifer and Kilpper-Balz 1984 
E. avium                                     Collins et al. 1984 
E. casseliflavus                        Collins et al. 1984 
E. durans                                   Collins et al. 1984 
E. gallinarum                           Collins et al. 1984 
E. malodoratus                           Collins et al. 1984 
E. hirae                                         Farrow and Collins 1985 
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E. mundtii                                      Collins et al. 1986 
E. raffinosus                                 Collins et al. 1989 
E. solitariusa                                     Collins et al. 1989 
E. pseudoavium                              Collins et al. 1989 
E. cecorum                                        Devriese et al. 1983; Williams et 
al.1989 
E. columbae                                 Devriese et al. 1990 
E. saccharolyticus                       Farrow et al. 1984; Rodrı´gues 
andCollins1990 
E. dispar                                     Collins et al. 1991 
E. sulfureus                                Martinez-Murcia and Collins 1991 
E. seriolicidaa                             Kusuda et al. 1991 
E. flavescensb                     Pompei et al. 1992 
E. asini                                     De Vaux et al. 1998 
E. villorumc                                    Vancanneyt et al. 2001 
E. haemoperoxidus                         Svec et al. 2001 
E. moraviensis                               Svec et al. 2001 
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E. ratti                                            Teixeira et al. 2001 
E. porcinusc                                  Teixeira et al. 2001 
E. gilvus                                        Tyrrell et al. 2002 
E. pallens                                      Tyrrell et al. 2002 
E. phoeniculicola                          Law-Brown and Meyers 2003 
E. canis                                          De Graef et al. 2003 
 
GENOME: 
The genome size is about 2 to 3.5 Mb and the G+ C content is 37 to 45 mol %. 
The genome of E.faecalis V583, the first vancomycin resistant clinical isolate 
from United States is completely sequenced and is useful in various research 
purposes . The genome of > 80 enterococcal strains has been sequenced. The 
genetic diversity of Enterococci is due the acquisition of mobile DNA like 
plasmids, transposons and phages and also a result of recombination of “ core” 
genomes. The medically important E.faecium  harbors an accessory genome 
into which exogenous genetic elements like Phage DNA are incorporated .It 
also possesses pathogenicity island, which is a large genetic element carrying 
virulence associated genes and plasmids with antibiotic resistant determinants 
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HABITAT: 
As outlined in Habitat, the enterococci are primarily members of the 
gastrointestinal microflora of humans, occurring in numbers as high as 108 
colony forming units (CFU) per gram of feces of adult individuals (Noble 1978; 
Huycke et al. 1998). Enterococcal populations in the intestinal tract fluctuate in 
size according to the age and physiological condition of the human host, being 
more numerous during early life (Tannock and Cook 2002). Diet also seems to 
affect the numbers of enterococci in fecal samples. Although E.faecalis appears 
to be the enterococcal species most commonly detected in human feces, in all 
likelihood most Enterococcus species are normal inhabitants of the 
gastrointestinal tract of humans. Since the enterococci are opportunistic 
pathogens, the incidence of each species found in human infections probably 
reflects the distribution of the different Enterococcus species in the human 
gastrointestinal tract.  
This site is believed to represent an important reservoir for strains associated 
with disease; from this location they may migrate to cause infections and can 
also disseminate to other hosts and environmental surfaces. E. faecalis is 
usually the most frequent enterococcal species isolated from human clinical 
specimens, representing 80–90 percent of the isolates, followed by E. faecium 
which is found in 5–10 percent of enterococcal infections. The other 
enterococcal species are identified less frequently. However, clusters of 
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infections with E. casseliflavus and E. raffinosus  have been reported. 
Therefore, the distribution of species varies with each clinical setting. Although 
less frequently or even rarely, several of the other enterococcal species, 
including E. avium, E. cecorum, E. dispar, E. durans, E. gallinarum, E. gilvus, 
E. hirae, E. mundtii, E. pallens, and E. faecalis variant strains, have also been 
isolated from human sources. E. columbae, E. haemoperoxidus, E. malodoratus, 
E. moraviensis, E. porcinus, E.  , E. ratti, E. saccharolyticus, and E.sulfureus 
have not been isolated from human sources. 
The comparison of data from different publications and the evaluation of the 
real incidence of the different species of enterococci as members of the 
intestinal microflora or as members of the microflora in other body sites have 
been impaired due to differences in the methodology used and the changes in 
the taxonomy of the genus. 
Enterococcus as a commensal: 
Commensalism is the relationship between two organisms in which one or both 
the organisms gets benefits and the other organism is not harmed. In the colon 
of nearly all humans and most animals enterococci are minor residents, present 
at ~108 colony forming units per g of faeces  Enterococci have effectively 
evolved various genetic traits which helps maintain their stable colonisation. 
Commensal isolates of E. faecium and E. faecalis are genetically distinct 
compared to infection isolates. The differences may be unclear, however, since 
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immunocompromised patients are more susceptible to infection even with 
commensal strains  
 
Enterococcal  Infections : 
The enterococci inhabit the gastrointestinal tract and the genitourinary tract in 
humans and other animals. Enterococci are frequent causes of nosocomial 
infections and may cause urinary tract infection, bacteremia, infective 
endocarditis, biliary tract infection, intra-abdominal abscess complicating 
diverticulitis, peritonitis and wound infection. 
 
PATHOGENESIS OF ENTEROCOCCAL INFECTIONS: 
To cause disease enterococci must colonise host tissues, defend against host 
immune mechanisms and express factors that enable persistence. Multiple 
factors are known that regulate the virulence of Enterococcus species, for 
example ability to colonise the gastrointestinal tract, ability to adhere to a 
variety of extracellular matrix components, including vitronectin, 
thrombospondin and lactoferrin, and ability to adhere to oral cavity epithelia, 
urinary tract epithelia and human embryo kidney cells (Fisher and Phillips 
2009).  Pathogenicity of enterococci has been related to several key virulence 
traits associated with adhesion, translocation and immune evasion.  
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Whereas enterococci are thought to account for no more than 1% of the adult 
intestinal microflora, the medical importance of enterococci outweighs their 
relative abundance . Of  the 26 species that have been proposed to belong to the 
genus, only 11 (E. avium, E. casseliflavus, E. durans, E. dispar, E. faecalis, E. 
faecium, E. gallinarum, E. hirae, E. mundtii, E. pseudoavium, and E. raffinosus) 
have been described as associated with human disease . E. faecalis accounts for 
80-90% of enterococcal isolates of clinical origin, with E. faecium the second 
most prevalent enterococcal species. Despite the lower frequency of isolation 
from clinical settings, E. faecium isolates are disparately resistant to treatment 
with antimicrobial chemotherapy. 
Although normally commensal in nature, enterococci are responsible for 
approximately 10% of urinary tract infections and 16% of nosocomial urinary 
tract infections . They are also commonly isolated from wound infections of the 
abdominal area as well as those from crushing injuries . Enterococcal 
bacteremia is the third leading cause of nosocomial bacteremia  with an 
estimated fatality rate of 28 to 58% . Enterococci are also responsible for 
between 5 and 20% of cases of bacterial endocarditis . Enterococci have been 
described as one of the most destructive agents that cause postoperative 
complications of cataract surgery .  
Up to 13% of bacteriologically confirmed cases of neonatal sepsis have 
been attributed to enterococci . Those who are elderly or have an underlying 
compromising situation are predisposed to enterococcal infection, especially in 
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the hospital environment. This is a significant observation given the ability of 
enterococci to colonize surfaces of the hospital environment and persist on 
fingertips and dry surfaces. As a result, enterococci seeding the clinical 
environment may be more easily spread if infection control measures are poorly 
implemented.  
CLINICAL SYNDROMES: 
Urinary tract infections: 
Enterococci have become the second most common agent recovered from 
nosocomial urinary tract infection (UTI). UTIs are the most common of the 
enterococcal infections: enterococci have been implicated in approximately 
10% of all UTIs and in 16% of nosocomial UTIs. Enterococcal bacteriuria 
usually occurs in patients with underlying structural abnormalities and/or in 
those have undergone urologic manipulations. 
 
Bacteremia and Endocarditis: 
Enterococcal bacteremias can usually be traced to enterococcal infections at 
other sites besides theurinary tract (e.g., intravenous catheter infections, biliary 
tract infection, gastrointestinal/genitourinaryinfections) and are most often 
hospital-acquired. The organisms can also gain entry into the 
bloodstreamthrough intra-abdominal or pelvic abscesses, wounds, decubitus 
ulcers, or intravenous access devices.Risk factors for the development of 
enterococcal bacteremia include advanced age, immunosuppression,underlying 
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diseases and conditions (e.g., prematurity, diabetes, malignancy, congestive 
heart failure, renalinsufficiency, deep-seated infections, prior gastrointestinal, 
genitourinary, or respiratory tractinstrumentation, long-term hospitalization, 
indwelling devices, and the use of broad-spectrum antibioticshaving little or no 
anti-enterococcal activity (e.g., cephalosporins). Bacteremias caused by E. 
Faecium are associated with a poorer prognosis than those due to E. faecalis 
primarily because of increasedantimicrobial resistance among the former 
species and the inherent difficulties of adequately treating moreresistant 
isolates. 
Enterococci, particularly E. faecalis, are also a common cause of prosthetic 
valve endocarditis. Endocarditis usually occurs in older male patients with 
underlying valvular disease orwith prosthetic valves and is generally subacute in 
clinical presentation, with patients having fevers, weight loss, malaise, and other 
vague constitutional symptoms. Endocarditis in these patients often follows 
procedures involving the gastrointestinal (e.g., transrectal prostatic biopsies, 
colonoscopy, fiberoptic sigmoidoscopy) or genitourinary (e.g., cystoscopy, 
prostatectomy) tracts. Complications of this infection include embolic 
phenomena frequently involving the CNS. In up to half of patients, enterococcal 
endocarditis results in acute heart failure that requires valve replacement 
Enterococci are more causative agents of both community acquired and hospital 
associated endocarditis especially in elderly, debilitated patients with comorbid 
conditions. It can cause both native and prosthetic valves, mitral and aortic 
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valves affected commonly. E.faecalis is isolated more frequently than E.faecium 
and other species. Malignant and inflammatory conditions and procedures 
involving genitor urinary or gartro intestinal tracts is the source of origin.  
Typical presentation involves a sub acute course with fever, malaise, weight 
loss, cardiac murmur and less than frequent peripheral signs. Heart failure is the 
common complication followed by embolic penomina, the most important end 
organ being brain. Mortality is mainly due to heart failure or embolization and 
the overall mortality rate ranges from 11% to 35%. 
Meningitis: 
Enterococcal meningitis is a rareenterococcal infection that may be seen in both 
adults and children.834 Enterococcal meningitis maydevelop spontaneously or 
as a postoperative infection. Individuals with spontaneous 
enterococcalmeningitis usually have enterococcal infection at other sites, have 
severe underlying disease, and haveconcomitant enterococcal bacteremia more 
frequently than those with postoperative infections. Underlying disease in 
patients with spontaneous meningitis include malignancy, diabetes, renal 
failure,and treatment with immunosuppressive agents. Patients with postsurgical 
enterococcal meningitis usually have an antecedent history of intracerebral 
hemorrhage, CNS neoplasms, head trauma, and hydrocephalus. Patients with 
this condition often have intraventricular catheters, surgical site CSF leakage, or 
ventriculoperitoneal shunts in place prior to diagnosis. In these cases, fever, 
obtundation, andmeningismus are usually present, and the CSF indices include 
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high white blood cell counts, elevatedprotein, and low or normal glucose. 
Postsurgical enterococcal meningitis may or may not be associated with 
enterococcal infections at other sites. In a review of enterococcal meningitis, E. 
faecalis accounted for 76% of isolates, and 15 of the 25 cases that were due to 
E. faecium were caused by vancomycin-resistant strains. 
 
 
Intraabdominal,pelvic and soft tissue infections: 
Intra-abdominal and pelvic infections are the next most commonly encountered 
infections. However,cultures from patients with peritonitis, intra-abdominal or 
pelvic abscesses, biliary tract infections, surgical-site infections, and 
endomyometritis are frequently polymicrobial, and the role of enterococci in 
this setting remains controversial. Enterococci are being recovered from wound 
infections at an increasing rate, which likely results from increased antibiotic 
usage and emerging resistance among these organisms. 
Enterococci produce spontaneous peritonitis in cirrhotic patients and patients on 
chronic ambulatory peritoneal dialysis. It is usually isolated along with gram 
negatives and anaerobes and its presence indicates treatment failure and 
increases the postoperative complications, and death. The emergence and spread 
of VRE and multi-drug resistant E.faecium isolates worsens the situation 
further.  
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Enterococci ranks Third amongst the causative agents of hospital acquired 
surgical-site infections. E.faecalis is the common species isolated Enterococci 
often colonize the decubitus ulcer and diabetic foot and can be a source of bone 
infections. 
 
Other infections: 
Enterococcal infections of the respiratory tract or the central nervous system, as 
well as otitis, 
sinusitis, septic arthritis, and endophthalmitis may occur but are rare. 
Enterococci are often found in wound andsoft tissue infections (e.g., burns, 
decubitus ulcers) with other facultative and anaerobic bacteria, 
andcomplications associated with such infections (e.g., enterococcal 
osteomyelitis) are rare 
LABORATORY DIAGNOSIS: 
Collection, transport and storage of specimens: 
  Standard procedures for collection and transport of blood, urine, or wound 
specimens should be followed. The specimens should be cultured as soon as 
possible with minimum delay. Trypticase soy or brain-heart infusion agar 
supplemented with 5% sheep blood is routinely used to culture enterococci. 
Enterococci grow well at 35ºC in the presence of CO2  but do not require a high 
level of CO2 for growth. If the clinical specimen is obtained from a 
contaminated site or is likely to containing bile esculin azide, colistin-nalidixic 
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acid, phenulethyl alcohol, chromogenic subrates, or cephalexin-aztreonam-
arabinose agar should be used for isolation of enterococci. 
Direct examination: 
The direct microscopic examination of gram stained smears of normally sterile 
clinical specimens like blood is useful in diagnosing Enterococcal infections. 
However, only a presumptive report of “presence of Gram positive cocci” can 
be given in case of nonsterile specimens. Direct detection of Enterococci 
especially VRE from clinical specimens and surveillance specimens (feces, 
rectal swab) by using conventional and real-time PCR based methods have been 
developed and evaluated. 
 A multiplex real-time PCR assay (Light cycler septifasttest) for rapid detection 
and identification of major pathogens of nosocomial bacteremia in whole blood 
is available for use in the US. 
 
Isolation procedures: 
Clinical specimens from normally sterile body sites, can be plated onto tryptic 
soy agar, brain heart infusion agar or blood agar base containing either 5% 
sheep, horse or rabbit blood for primary isolation of Enterococci. Samples for 
blood culture are inoculated into conventional 
blood culture systems. Most of the clinically relevant species grow well at 35 to 
37ºC. For specimens obtained from non-sterile sites especially when 
contaminated with gram negative bacilli, selective media containing sodium 
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azide, bile salts, antibiotics and esculin , tetrazolium can be used for primary 
isolation. However not all Enterococci grow on selective media. Use of 
enrichment broth ( Enterococcosel broth- BEA medium with 6µg vancomycin) 
increases the recovery rate of Enterococci especially VRE from feces and rectal 
samples especially surveillance specimens. Various chromogenic media from 
different manufacturers also have been evaluated for the primary isolation. 
 
Identification of Enterococcus species: 
The genus identification of a catalase negative, Gram positive coccus as “ 
Enterococcus” is based on the above said tests in genus description. 
Enterococal species can be classified into five physiological groups of species 
as proposed by Facklam and Collins,based on acid production from mannitol 
and sorbose and hydrolysis of arginine . Further speciation is based on acid 
production from sugars like arabinose, sorbitol, raffinose, sucrose, pyruvate, 
trehalose and reduction of 0.04% tellurite, motility and pigment production. 
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Various commercial identification systems – manual, semi automated and 
automated systems like API 20S, API Rapid ID32STREP, Crystal gram positive 
ID system, Gram positive identification card of Vitek system etc..are available. 
These are reliable for the detection of most common species E.faecalis and to a 
lesser extent E.faecium. 
 
Molecular methods 
The introduction of various molecular techniques has substantially improved the 
ability to discriminate enterococcal isolates and has provided critical insights 
into 
epidemiological aspects of enterococcal infections. As a result of the use of 
more discriminatory typing methods, it has been possible to demonstrate that 
strains can be exogenously acquired by direct and indirect contact among 
patients. The first molecular techniques developed for typing of enterococci 
were the analysis of plasmid profiles and the restriction enzyme analysis (REA) 
of genomic DNA by conventional electrophoresis. 
Ability to discriminating among enterococcal strains was noted with the use of 
techniques involving the analysis of chromosomal DNA restriction 
endonuclease profiles by pulsed-field gel electrophoresis (PFGE) by either 
field-inversion gel electrophoresis (FIGE) or ideally, counter-clamped 
homogeneous electric-field electrophoresis. 
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Multi locus enzyme electrophoresis (MLEE) , Ribotyping and the polymerase 
chain reaction (PCR)-based typing methods, such as the random amplified 
polymorphic DNA (RAPD)-PCR assay and the repetitive element sequence 
(REP)-PCR have also been used to investigate the genetic relationship among 
enterococcal strains. Sequencing of PCR products and restriction fragment 
length polymorphism (RFLP) analysis of PCR products have been used to trace 
and to determine differences among specific resistance genes in enterococci, 
therefore representing additional tools for typing resistant strains. Analysis of 
SmaI restriction digests of genomic DNA by PFGE is widely useful for 
studying enterococcal species. 
Antimicrobial Resistance: 
Resistance to several commonly used antimicrobial agents is a remarkable 
characteristic of most of the enterococcal species. Moreover, the majority of the 
information available is based on studies with E. Faecalis and E. faecium, the 
two species that are more frequently associated with human infections. 
Antimicrobial resistance can be classified as either intrinsic or acquired. 
Intrinsic resistance is related to inherent or natural chromosomally encoded 
characteristics present in all or most of the enterococci. Furthermore, certain 
specific mechanisms of intrinsic resistance to some antimicrobial agents are 
typically associated with a particular enterococcal species or group of species. 
In contrast, the occurrence of acquired resistance is more variable, resulting 
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from either mutation in existing DNA or acquisition of new genetic 
determinants found in plasmids or transposons. 
 
Intrinsic resistance of enterococci: 
Enterococcal intrinsic resistance involves two major groups of antimicrobial 
therapeutic drugs: the aminoglycosides and the b-lactams. Because of the poor 
activity of several antimicrobial agents against enterococci due to intrinsic 
resistance, the recommended therapy for serious infections (i.e. endocarditis, 
meningitis, and other systemic infections, especially in immunocompromised 
patients) includes a combination of a cell-wall-active agent, such as a B-lactam 
(usually penicillin) or vancomycin, combined with an aminoglycoside (usually 
gentamicin or streptomycin).  
 
These combinations overcome the intrinsic resistance exhibited by the 
enterococci and a synergistic bactericidal effect is generally achieved since the 
intracellular penetration of the aminoglycoside is facilitated by the cell-wall-
active agent. 
In addition to the intrinsic resistance traits, enterococci have acquired different 
genetic determinants that confer resistance to several classes of 
antimicrobials,including chloramphenicol, tetracyclines, macrolides, 
lincosamides and streptogramins, aminoglycosides, blactams, glycopeptides, 
and, more recently, quinolones. 
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Acquired resistance of enterococci to ß –Lactams and aminoglycosides 
antibiotics: 
Aminoglycoside resistance: 
Over the past decades, the occurrence of acquired antimicrobial resistance 
among enterococci, especially high-level resistance (HLR) to aminoglycosides,  
𝛽 -lactams, and resistance to glycopeptides (especially vancomycin), has been 
increasingly reported. These resistance traits are of particular clinical relevance 
as they confer resistance to agents used in the treatment of serious enterococcal 
infections and can abolish the activity of the therapeutic regimens with proven 
bactericidal activity against enterococci. Isolates that are resistant to the cell-
wall-active agent or have HLR to aminoglycosides are resistant to the 
synergistic effects of combination therapy and constitute an even more serious 
problem concerning the effective management of enterococcal infections. 
Therefore, the detection of resistance to these groups of antimicrobial agents is 
important to predict the likelihood of synergy by using antimicrobial association 
as a therapeutic strategy. 
Enterococcal isolates exhibiting HLR to one or more aminoglycosides have 
been described with increasing frequency (Murray 1990, 1998; Antalek et al. 
1995;Leclercq 1997; Huycke et al. 1998; Strausbaugh and Gilmore 2000) and 
are now present in large proportions in several geographic areas. Strains 
expressing acquired HLR to aminoglycosides usually have minimal inhibitory 
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concentrations (MIC) >2000 lg/ml and cannot be detected by diffusion tests 
with conventional disks. 
Special tests using high-content gentamicin and streptomycin disks (Sahm and 
Torres 1988), as well as a single dilution method, were developed to screen for 
this type of resistance (Swenson et al. 1995). Strains exhibiting HLR to 
penicillin and ampicillin due to altered penicillin-binding proteins have also 
disseminated widely in the past several years (Murray 1990, 1998; Boyce et al. 
1992; Huycke et al. 1998; Strausbaugh and Gilmore 2000), and strains 
producing β-lactamase have been identified (Murray 1990; Gordonet al. 1992). 
 
ß -Lactam antibiotic: 
Many strains of enterococci, particulary E. faecium, are intrinsically resistant to 
β-lactam antibiotics because they possess proteins with low binding affinity for 
these drugs. In particular, the cephalosporins are uniformly ineffective against 
enterococci and shoud not be tested. In general, ampicillin is more effective 
against enterococci than penicillin in vitro (Leclercq et al, 1988). 
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Vancomycin: 
Definition: 
Vancomycin is a glycopeptide antimicrobial produced by the soil bacteria 
Streptomyces orientalis. It was developed and introduced in the 1950s. Another 
glycopeptide authorised for use in humans in Sweden is teicoplanin. 
Glycopeptides interfere with the cell wall production resulting in a destabilized 
cell wall and lysis of the bacteria. When the bacterial cell wall is synthesized, 
polysaccharide-pentapeptide complexes are linked together via a 
transpeptidation reaction in which the end amino acid of the pentapeptide is 
removed. Glycopeptides interferewith this process by binding tightly to the D-
Alanyl-D-Alanin (D-Ala-DAla) end of the pentapeptide and hiding it from the 
transpeptidase that is to catalyse the cross-linking in the peptidoglycan 
synthesis. 
Vancomycin is active against most Gram positive bacteria whereas the majority 
of Gram negatives are resistant. It is considered a drug of “last resort” and has 
been classified as critically important for human medicine for treatment of 
patients with severe infections with multi-drug resistant Enterococcus spp. and 
meticillin resistant Staphylococcus aureus (MRSA) as the main indications. 
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Mode of action: 
Like many antibiotics (including the penicillins), vancomycin acts by interfering 
with the construction of cell walls in bacteria, blocking the enzymes necessary 
for bacterial cell wall assembly. 
 
Resistance to vancomycin: 
History: 
Scientists introduced Vancomycin into hospitals more than forty years ago in 
response to new strains of Staphylococci developing resistance to penicillin. 
The introduction of methicillin decreased the use and importance of 
Vancomycin for a few years; however, when methicillin-resistant S. aureus 
strains appeared in the past two decades, the glycopeptide antibiotic was 
reinstated as a therapeutic agent. 
Vancomycin is now seen as the last-resort drug because it is often the last 
opportunity that a physician may have to eliminate infections caused by multi-
drug resistant bacteria. 
 
Genes of vancomycin resistance: 
Until today, nine different variants of vancomycin resistance in enterococci 
have been described (vanA, B, C, D, E, G, L, M and N; Table 1) (Hegstadet al., 
2010; Lebreton et al., 2010; Xu et al., 2010; Boyd et al., 2008; Courvalin, 
2006). Among those, the three most common variants are the vanA, B and C 
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types with E. faecium carrying the vanA genotype as the most common 
combination (Fisher & Phillips, 2009; Werner et al., 2008). An additional 
variant (vanF) has also been described but thus far only in Paenibacillus 
popilliae (Patel et al., 2000). Since the vanF variant has a high similarity in 
amino acid sequences to the vanA variant, P. popilliae has been suggested as a 
possible origin for vancomycin resistance in enterococci (Patel et al., 2000). 
Other plausible sources are various glycopeptide producing organisms, even if 
genetic differences make an older common source more likely (Patel, 2003). 
Common to all variants of Vancomycin resistance in enterococci is the ability to 
cause a change in the structure of the pentapeptide incorporated in the 3 
dimensional web of peptidoglycans composing the bacterial cell wall: from the 
original D-Ala-D-Ala to either D-Ala-D-Lactate (D-Ala-DLac) or D-Ala-D-
Serine (D-Ala-D-Ser) (Courvalin, 2006). This shift results in a reduced affinity 
for Vancomycin by 1000 and  seven  times respectively (Fisher & Phillips, 
2009). 
In all different variants of vancomycin resistance are several genes involved in 
the alteration of the cell wall structure which results in the resistance. The 
number and organisation of these genes are somewhat similar among the 
different variants. For the vanA variant, the genes are organized as in Figure4. 
VanS is a sensor gene which in the presence of a glycopeptide 
phosphorylate, and thus activate the regulator gene vanR (Courvalin, 2006). 
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After activation of the gene complex, VanH mediates production of lactate from 
pyruvate which vanA uses to synthesize the alternative D-Ala-D-Lac end of the 
pentapetide (French, 1998). It is essential for resistance that production of the 
normal D-Ala-D-Ala end of the pentapetide does not continue. This is resolved 
by the vanX and vanY genes where vanX hydrolyzes and thereby interrupts the 
production of the pentapeptides, and vanY cleaves the pentapeptides that might 
still be produced (French, 1998; Arthur et al., 1996). In the absence of a 
glycopeptide, vanS initiates dephosphorylation of vanR resulting in deactivation 
of the gene (Courvalin, 2006).The function of the vanZ gene is not understood 
(Courvalin, 2006). 
 The mechanism of resistance has been best characterized for the vanA. It 
consists of cluster of seven genes found on the transposable (mobile) genetic 
element Tn1546. In the presence of an inducer like vancomycin, transcription of 
the genes necessary for resistance to vancomycin is activated as a result of the 
interactions of a sensory kinase and a response regulator.  
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           Figure : Peptidoglycan biosynthesis and the mechanism of vancomycin. 
           Association of the antibiotic to the C-terminal d-Ala–d-Ala of late 
           peptidoglycan precursors stops catalysed reactions by transpeptidases, 
           transglycosylases, and carboxypeptidases reproduced from Courvalin 
2006. 
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DIFFERENT TYPES OF VANCOMYCIN RESISTANCE FOUND IN 
ENTEROCOCCUS SPP. 
 
 
 
 
Phenotypic description: 
VRE strains have been classified by phenotypes and genotypes. Six types of 
glycopeptide 
resistance have already been described among enterococci. Three of them are 
the most common: the VanA phenotype, with inducible high-level resistance to 
vancomycin, as well as to teicoplanin, encoded by the vanA gene; the VanB 
phenotype, with variable (moderate to 
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high) levels of inducible resistance to vancomycin only, encoded by the vanB 
gene; and the VanC phenol type, with non inducible low-level resistance to 
vancomycin. 
The VanA and VanB phenotypes are considered the most clinically relevant and 
are usually associated with E. faecium and E. faecalis strains while the VanC 
resistance is a intrinsic characteristic of E. gallinarum (vanC1 genotype) and E. 
casseliflavus (vanC2 and vanC3 genotypes) strains (Clark et al. 1998; Huycke et 
al. 1998; Murray 1998; Cetinkaya et al. 2000). 
The remaining three types of enterococcal glycopeptides resistance seem to 
occur rarely and are encoded by genetic determinants that were recently 
recognized, named vanD (Perichon et al. et al. 2000). 
The details of vancomycin resistance have been best documented with the Van 
A gene cluster found on the transposon, Tn1546 (Arther and Courvalin, 1993; 
Arther et al., 1993). Van B isolates were initially believed to be inducibly 
resistant to more modest levels of vancomycin but are susceptible to 
teicoplanin. VanB resistance determinants also reside on large mobile elements 
that can be transferred from 1 strain of enterococcus to another (Quintiliani et 
al., 1993, 1994). 
The VanC resistance phenotype was described in E. gallinarum which 
demonstrate low-level resistance to vancomycin and susceptible to teicoplanin. 
In the United States, VanA and VanB account respectively for approximately 
60% and 40% of VRE isolate (Clark et al., 1993). 
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Certain limitations of this classification method have become evident over time. 
For example, the genetic determinants of the VanA Phenotype have now 
appeared in E. gallinarum and other enterococcal species (Dutka Malen et al., 
1994 ).  
 
Nevertheless, this phenotypic classification is still useful, because it usually 
corresponds well to the genetic classification and utilizes information that can 
be derived simply and inexpensively in laboratory (Elipoulos, 1997). 
 
Genotypic classification of VRE: 
VanA glycopeptide resistance: 
The vanA gene and other genes involved in the regulation and expression of 
vancomycine resistance (vanR, vanS, vanH, vanX, and vanZ) are located on a 
10,581.bp transposon (Tn1546) of E. faecium, which often resides on plasmid 
(Arther et al., 1993). The advantage of accumulating genes in plasmids is that, 
these regions of DNA can replicate independently of the bacterial genome, and 
can also be readily transferred from one cell to another. Resistance can therefore 
easily spread between species. In addition, these vancomycin-resistance genes 
are located on transposon elements, which can cut themselves out of one 
segment of DNA and move to another segment. These characteristics make it 
very easy for bacteria to transfer antibiotic resistance to other cells of the same 
(or different) species (Walsh and Christopher, 2001). VanA phenotype display 
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vancomycinandteicoplanin-inducible, transposon-mediated, high-level 
resistance to both vancomycin (MIC, 64 to1,000 µg/mL) and teicoplanin (MIC, 
16 to 512 µg/mL).1147 
 
VanB glycopeptide resistance: 
The vanB cluster genes is often located on the host chromosome and initially 
was thought not transferable to other bacteria. However, it can also occur on 
plasmids, and, even when it is chromosomal, this gene cluster has been 
transferable as part of large mobile elements, perhaps related to large 
conjugative transposons (Quintiliani et al., 1994). Strains with the vanB 
genotype (VanBphenotype) have acquired vancomycin-inducible resistance to 
various concentrations of vancomycin(MIC, 4 to 1,000 µg/mL) but remain 
susceptible to teicoplanin (MIC, 0.5 to 1 µg/mL), although rare vanB strains 
may also be resistant to the latter antibiotic. 
VanC glycopeptide: 
The genes encoding the VanC type of vancomyin resistance are endogenous, 
species-specific components of E. gallinarum (vanC-1)and E. casseliflavus/E. 
flavescens (vanC-2/vanC-3 (Navarro and Courvalin , 1994). 
 
VanE glycopeptide resistance: 
The vanE gene has recently been described in E. faecalis, which is resistant to 
low levels of vancomycin, with Minimal Inhibitry Consentration (MICs ) 
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16µg/ml ( Butz et al. 1990). Isolates that have the vanC genotype display 
intrinsic,constitutive, low-level resistance to vancomycin (MIC, 2 to 32µg/mL) 
and are susceptible to teicoplamin(MIC, 0.5 to 1 µg/mL). The vanC genotype 
corresponds to the intrinsic glycopeptide resistance seen in E.gallinarum, E. 
casseliflavus, and E. flavescens. This vanC gene cluster is not transferred by 
conjugation to other organisms, is generally constitutively expressed, and is 
chromosomal in origin. 
VanD glycopeptide resistance: 
The strain carring this resistance gene is E. faecium that inhibited by 
vancomycin at 64µg/ml . VanD appears to be located on the chromosome and is 
not transferable to other enterococci (Ostrowsky,1999). This vanC gene cluster 
is not transferred by conjugation  to other organisms, is generally constitutively 
expressed, and is chromosomal in origin. 
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 Organisation of VanA-type glyc opeptide resistance operon. The arrows show 
regulatory and resistance and the accessory coding sequences reproduced from 
Courvalin 2006. 
 
Epidemiology and control of VRE: 
Geographic distribution and spread within hospitals: 
Since their initial recovery from patients in the UK and France, VRE have been 
found in many other countries, including Australia, Canada, Denmark, Italy, 
Malaysia, and the US (Woodford et al., 1995). 
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Hospital outbreaks of infection or colonization have been reported with both 
VanA and VanB isolates (Boyce et al., 1995). Patients may be colonized 
simultaneously with more than one strain of VRE (Mato et al., 1996; Wade, 
1995). Stool isolates of VRE have included a 
number of different species such as E. faecalis, E. faecium, E.gallinarum, and 
E. avium (Bates et al., 1995). Fortunately, rates of stool colonization with VRE 
among hospitalized patients by far exceeds infection rates with these organisms 
(Lam et al., 1995;Montecalvo et al.,1995). Gastrointestinal tract colonizatin 
with VRE may persist for weeks or monthes, and single negative cultures may 
be intermixed with positive culters over time (Montecalvo et al., 1995). During 
outbreaks,enviromental cultures in hospital rooms have yielded VRE (Boyce et 
al., 1995; Mato et al., 1996 ; Slaughter et al., 1996). 
 
VRE in the community: 
In the USA, attention has focused on the epidemiology of VRE mainly in 
hospitals, and there is little evidence to suggest that transmission of VRE to 
healthy adults occurs to any significant extent in the community (Murray, 
1995). In a study in Texas, investigators failed 
to find any VRE in the feces of chickens (Murray, 1997). In addition,VRE could 
not be isolated from healthey volunteers in two studies (Murray, 1997 and 
Wade, 1995). Two cases of apparent community acquired VRE urinary tract 
infections in New York City have been reported (Friden et al., 1993). 
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The situation in Europe is quite different from that in the United States. In 
Europe, VRE have been isolated from sewage and various animal soureces 
(Bates, et al., 1995; Klare, et al., 1995). It has been suggested that the use of 
glycopeptide-containing animal feeds in some reigons of Europe may have 
contributed to such differences . In one study, VanA resistant E. faecium was 
isolated from frozen poultry and pork and from the feces of 12 of 100 non 
hospitalized inhabitants in a rural area ( Klare et al., 1995) VanA VRE have also 
be found in the feces or intestines of other farm animals (Devriese et al., 1996). 
These observations suggest a potential for VRE or the resistance genes of VRE 
to reach humans through the food chain or through contact with domesticated 
animals (Gordst et al., 1995) . 
 
Reservoirs: 
Although much has been learnt about the epidemiology of VRE in recent years, 
the most important reservoirs of VRE has not been reached. Subsequent 
investigations revealed that several of these patients resided in farms and that 
chickens and swine present on the farms were colonized with vancomycin-
resistant E. faecium. VRE has subsequently been recoverd from various animal 
sources in different European countries . The occurrence of VRE in such 
animals could be related to the fact that avopracin ( a glycopeptide) has been 
available as a feed additive for more than 15 years in the United Kingdom and 
other European countries (Aarestrup, 1995; Witte et al., 1995). It has been fed 
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to chickens, swine, and cattle. In the US, avopracin has not been used as a feed 
additive for animals, and culture surveys of a limited 
number of chickens in several cities have failed to detect VRE (Harrison et al., 
1995). Further studies of animal-based food products are needed to determine if 
food items represent a community reservoir for VRE in that country ( Boyce, 
1997). 
 
Mode of transmission: 
Transmission of VRE by hospital workers whose hands become contaminated 
with the organism while caring for patients is probably the most common mode 
of hospital acquired infection transmission (Tornieporth et al., 1996; Zervos et 
al., 1987). Transmission of VRE may also occur by way of contaminated 
medical,surgical equipment, although this is probably much less important than 
transmission by the hands of personnel. Electronic thermometers contaminated 
with the outbreak strain were epidemiologically implicated in an outbreak 
described by Livornese et al., (1992). 
Since enterococci may remain viable for several days to weeks on dry surfaces, 
it seems that contaminated surfaces may act as a source from which personnel 
may contaminate their hands or clothing (Boyce et al., 1994). However, further 
studies are necessary to determine the extent to which these items contribute to 
the transmission of VRE (Boyce et al.,1997). 
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Prevention and control: 
The epidemiology of VRE has not been completely elucidated; certain patient 
populations are at high  risk for VRE infection or colonization . These include 
critically ill patients or those with severe underlying disease or 
immunosuppression, such as intensive care unit (ICU) patients or patients in 
oncology or transplantation. Those who have had an intra-abdominal or 
cardiothoracic surgical procedure, and those who have had prolonged hospital 
stay or received multiple antimicrobial agents (Boyce et al., 1994; Boyle et al., 
1993; Centers for Disease Control and prevention. 1993; Friden et al., 1993; 
Handwerger et al., 
1993; Karanfil et al., 1992 and Montecalvo et al., 1994). Because enterococci 
are part of the normal flora of the gastrointestinal tract and the female genital 
tract, most infections with those organisms have been attributed to the patient’s 
endogenous flora (Murray, 1990). However, recent reports have demonstrated 
that enterococci, including VRE, can be spread by direct patient-to patient 
contact or indirectly via transient carriage on the hands of personnel (Boyce et 
al., 1994), Contaminated environmental surfaces (Boyce et al., 1994; Karanfil 
et al., 1992), or patient care equipment (Livornese et al., 1992). 
In an effort to control the hospital acquired infection transmission of VRE, 
Hospital Infection Control Practices Advisory Committee (HICPAC) published 
recommendations in February 1995 (Centers for Disease Control and 
Prevention. 1995). These recommendations mainly focused on ; prudent use of 
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vancomycin, education of hospital staff, effective use of the microbiology 
laboratory, implementation of infection control measures (including the use of 
gloves and gowns) and isolation of patients, as appropriate to specific 
conditions ( Boyce, 1997; Centers for Disease Control and prevention. 1995). 
 
Education programs: 
Continuing educational programs for hospital staff (including students, 
pharmacy personnel, nurses, laboratory personnel) should include information 
about the epidemiology of VRE (Centers for Disease Control and prevention, 
1995). Because detection and containment of VRE require high performance 
standards for hospital personnel, special awareness and educational sessions 
may be indicated (Boyce, 1997). 
 
Role of the microbiology laboratory in the detection of VRE: 
Early detection of patients colonized or infected with VRE is an essential 
component of any hospital program designed to prevent nosocomial 
transmission of VRE (Boyce, 1997 ). Once the prevalence of VRE reaches high 
levels within an institution, prevention of transmission is more difficult. The 
microbiology laboratory is the 1st  line of defense against the spread of VRE in 
the hospital . The ability of the laboratory to identify enterococci and to detect 
Vancomycin resistance accurately is essential in recognizing VRE colonization 
and infection and avoiding complex, costly containment efforts that are required 
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when recognition of the problem is delayed ( Centers for Disease Control and 
Prevention,1995).  
In addition, cooperation and communication between the laboratory and the 
infection control program would facilitate control efforts (Friden, et al., 1993; 
Karanfil, et al., 1992). 
Enterococci may also be tested for vancomycin resistance by using Polymerase 
Chain Reaction (PCR) assays designed to detect the genes responsible for 
glycopeptide resistance in these organisms (Clark,et al., 1993; Swenson, et al., 
1992). Such testes may be particulary helpful in detecting VanB or VanC 
containing strains with low-level resistance to vancomycine (Swenson, et al., 
1992). Testing VRE isolates for susceptibility to teicoplanin by using simple 
disk diffusing tests will differentiate between VanA (teicoplanin-resistant) and 
VanB (teicoplanin-susceptible) strains in most instances (Satake, et al., 1999) 
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AIMS AND OBJECTIVES 
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1. To isolate and speciate enterococci from cases of nosocomial infection. 
 
2. To determine the antibiotic susceptibility pattern of the isolates and the 
pattern of vancomycin resistance. 
 
3. Screening for  vanA gene using molecular methods. 
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MATERIALS AND METHODS 
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This study was conducted during the period from April 2017 to May 2018 at the 
Department of Microbiology, Tirunelveli Medical College , Tirunelveli. 
 
INCLUSION CRITERIA: 
During the study a total of about 100 non duplicate clinical isolates of 
Enterococci were collected from different clinical samples like clinical 
specimens such as urine, blood, 
pus, tissue fluids obtained from  both in-patient and out-patient departments of 
Tirunelveli Medical College. The Enterococcal species were identified by 
standard biochemical techniques.  
 
EXCLUSION CRITERIA: 
 
 Patients who were already on treatment with vancomycin .  
 
  A detailed history regarding previous hospital admission within two years, 
antibiotic intake in previous six months was elicited from every patient. 
 
Ethical clearance: 
As this study involved the clinical samples from the patients, institutional 
ethical clearance was obtained before the commencement of the study. 
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Informed consent: 
Informed consent was obtained from all persons involved in this study. 
 
Proforma: 
A filled in proforma was obtained from the patients with details like name, age, 
sex, ward, clinical diagnosis, risk factors, surgical intervention, hospital stay, 
previous use of  Vancomycin or  any other antibiotics and other parameters 
relevant to the study. 
 
Sample storage: 
The Enterococcal isolates were sub-cultured on to nutrient agar slope and stored 
at 2 to 80C. The Enterococcal  isolates were sub-cultured every fortnight. 
 
Primary isolation and identification of Enterococci : 
Samples: 
During the study period sample collected from were urine, blood, pus, tissue 
fluids were collected from those patients attending outpatient& inpatient 
Department  in Tirunelveli Medical College . Samples which were received was 
processed within two hours of receipt as per standard procedures. 
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Microscopy: 
  A primary smear is made from the sample and stained with Gram stain, gram 
positive cocci which appear mainly in pairs slightly ovoid in shape and 
may appear in short chains, or as single cells were suspected of being 
enterococcus. 
 
Biochemical reactions: 
Catalase test:  
It was done by slide test or tube test. 
Slide test- 
 A single colony taken from nutrient agar plate was placed over the clean glass 
slide, to this one drop of 3% H2O2(hydrogen peroxide) was added, 
effervescence was not observed. When effervescence  appeared it was a 
negative test. 
 
Tube test- 
1ml of 3% H2O2 was taken in a small test tube, small amount of bacterial 
growth was introduced with the help of glass rod or plastic applicator stick ,  
and presence of effervescence was not  observed. 
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Bile esculin agar: 
The  suspected  Enterococcal  isolates were then inoculated onto Bile esculin 
agar ( containing 40% bile) , incubated aerobically at 370C overnight. The next 
day the isolates showing black discoloration of the medium due to hydrolyse of 
esculin to esculetin and dextrose which reacts with ferric citrate were identified 
as BEA positive. 
Aesculin agar plates were inoculated with the suspected isolates and incubated 
at 370C for 48 hr. aerobically. Isolates that produced blackening of the medium 
were tentatively identified as 
enterococci. 
Growth in 6.5% NaCl: 
Two or three colonies of the suspected enterococci were inoculated into nutrient 
broth containing 6.5% NaCl. The inoculated broth was incubated at 370C for 3 
days aerobically. Growth was indicated by development of turbidity. 
 
Heat tolerance test: 
The suspected Enterococcal isolates along with the control strains were tested 
for heat tolerance by inoculating them into BHI broth and incubating them 
along at 600C for 30 minutes in a water bath. Subcultures from the broth were 
done on blood agar and Mac Conkey agar before incubation and at intervals of 
10 min, 20min and 30 minutes after incubation . ATCC E.faecalis 29212 was 
used as a positive control. 
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The growth of the positive control was checked before reading other isolates. 
The ATCC control strain  growth both before and after heating the broth at 600C 
for 30 minutes was noted. The isolates showing growth before and after 30min 
of incubation at 600C were taken as heat tolerant Enterococcal isolates . 
 
Salt tolerance: 
Salt tolerant property of the suspected Enterococcal isolates were tested by 
inoculating 2 to 3 identical colonies of suspected isolates along with control 
strains into a tube containing nutrient broth with 6.5% sodium chloride and 
incubated at 370C for 24-72 hours. 1% bromo cresol purple was  added as an 
indicator to detect yellow discoloration on growth. The broth showing turbidity 
with or without yellow discoloration was taken as positive reaction and was 
confirmed by subculturing the broth on blood agar / Mac Conkey agar. The salt 
tolerant isolates grew well even in the presence of 6.5% NaCl. Salt tolerant , 
BEA positive isolates, which were able to grow on MacConkey agar and at 
temperatures of > 45ºC were identified as Enterococci and selected for further 
speciation. 
Speciation of the Enterococcal isolates was done based on the Faklam and 
Collins conventional identification scheme. Enterococci were classified into the 
physiological groups I-V based primarily on arginine dihydrolysis, fermentation 
of mannitol and sorbose .  
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Further speciation was based on acid production from specific carbohydrates 
and motility and pigment production. 
 
Arginine dihydrolysis: 
Arginine dihydrolysis was tested by inoculating the isolate into a tube of 
Moeller’ s decarboxylase broth containing arginine and a control tube ( without 
arginine), overlaid with sterile liquid paraffin and incubated for seven days at 
370C . Control strains were also included in the test. Development of deep 
purple colour due to alkalinisation after an initial change to yellow colour was 
read as positive reaction. 
Persistant yellow color indicates negative reaction. 
 
Identification of Enterococcus species 
Identification E.faecalis E.faecium 
Gram Stain Cocci in pairs & short 
chain 
Cocci in pairs & short 
chain 
Catalase Negative Negative 
Motility Nonmotile Nonmotile 
Blood Agar  α – or non hemolytic, 
small, cream 
 α – or non hemolytic, 
small, cream 
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colored,smooth colonies 
with entire edge 
colored,smooth colonies 
with entire edge 
MacConkey agar Lactose fermenting, 
majenta coloured 
colonies 
lactose fermenting, 
majenta coloured 
colonies 
Bile esculin agar Positive Positive 
Heat tolerance survives a temperature of 
60ºc for 30 minutes. 
survives a temperature of 
60ºc for 30 minutes. 
 
Arginine dihydrolysis Positive Negative 
 
 
ANTIBIOTIC SUSCEPTIBILITY TESTING : 
Antibiotic susceptibility testing of all the Enterococcal isolates and the 
screening and confirmatory tests for the detection of specific resistance 
mechanism of  Glycopeptide resistance were performed as per CLSI Standards. 
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ANTIBIOGRAM BY KIRBY-BAUER DISC DIFFUSION 
METHOD : 
The antibiotic susceptibility pattern of the isolates was determined by on 
Mueller –Hinton agar (MHA) .The bacterial inoculums was prepared by 
inoculating few identical colonies in a Nutrient broth and incubated for 3-6hrs. 
It was standardized with 0.5 Mc Farland turbidity 
standard (1.5×108 CFU/ml) before inoculation, if the bacterial suspension is too 
thick it should be diluted to match the standard and if it is less turbid, it has to 
incubated further. 
After standardization, a sterile swab is dipped in that broth and the excess fluid 
is squeezed out by pressing on the side of the test tube, and it was streaked on 
the surface of the agar three times, turning the plate at 60º each time to produce 
a lawn culture of the organism. Then it is allowed to dry and the antibiotic discs 
were placed over the lawn culture within 15 minutes of inoculation. 
The antibiotics tested were as follows Antibiotic susceptibility testing  by kirby-
Bauer disk diffusion method as per the CLSI (clinical Laboratory Standards 
Institue) guideline again Vancomycin (30 microgram) , Teicoplanin (30 
microgram) , Linezolid (30 microgram) , Penicillin G (10 microgram), 
Tetracycline (30 microgram) , Ciprofloxacin (5 microgram) , Chloramphenicol  
(30 microgram), Doxycycline (30 microgram) and HLG (120 microgram). 
 
57 
 
 
 
All the materials and antibiotic disc were procured from Himedia laboratories 
Pvt.Ltd. Mumbai. The inoculated plates were incubated aerobically at 37ºC 
overnight. Next day the zone of inhibition of the bacterial growth around each 
disc was measured using ruler under reflected light except for Vancomycin and 
read through transmitted light. The interpretation as susceptible, intermediate 
and resistant were done according to the CLSI guidelines.(Appendix) 
 
DETECTION OF VANCOMYCIN RESISTANCE BY VANCOMYCIN 
SCREEN AGAR : 
Presumptive identification of Vancomycin resistance was done by Vancomycin 
screen agar (i.e) brain heart infusion (BHI) agar containing 6 µg /ml 
Vancomycin. 10µl of 0.5 McFarland suspension of the isolate ,along with 
positive and negative control strains, was spot inoculated onto the agar surface 
and incubated aerobically for 24hrs at 35±2ºC.Growth of > 1 colony indicated  
presumptive Vancomycin resistance which was confirmed by determining the 
Minimum inhibitory concentration (MIC) for vancomycin. 
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MIC for vancomycin- resistant Enterococcus by E strip method : 
Minimum inhibitory concentration (MIC) value for Vancomycin were   
determined using Hi Comb MIC Strip (Hi-media, Mumbai). Any Enterococcus 
was considered VRE if the MIc was ≥16microgram/ml.  
E-test was done to determined the minimum inhibitory concentration of 
Vancomycin for all the clinical isolates of enterococci. The E-test is comprised 
of two strips: Strip A: 240-0.01 µg and Strip B: 4-0.001 µg (Hi Comb, MIC test, 
HIMEDIA laboratories).The results were interpreted as per CLSI guidelines. 
MIC MINIMUM INHIBITORY CONCENTRATION FOR 
TEICOPLANIN: 
 
E-test was done to determined the minimum inhibitory concentration of 
Teicoplanin  for  the VRE  isolates .The glycopeptide teicoplanin MIC was also 
tested in the same method as described above for Vancomycin  using Hi Comb, 
MIC test, The E-test is comprised of two strips: Strip A: 240-0.01 µg and Strip 
B: 4-0.001 µg HIMEDIA laboratories. Any Enterococcus was considered 
Teicoplanin resistant  if the MIC was ≥32 microgram/ml.  
 
MOLECULAR METHOD FOR THE DETECTION OF VRE: 
Polymerase chain reaction (PCR) assay was performed  for the detection of 
Vancomycin resistance genes in Enterococci especially in E.faecium, and 
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E.faecalis by the PCR Kit procured from Helini Biomolecules,Chennai. The 
DNA was extracted from the Enterococcal 
isolates by using Helini Pure Fast Bacterial Genomic DNA Mini Spin 
Purification Kit and subjected to PCR and the gene product viewed by gel 
electrophoresis. 
Extraction of DNA from the Enterococcal isolates : 
1. 1ml of overnight bacterial culture centrifuged at 6000rpm for 5 min. 
2. Supernatant discarded 
3. Pellet is suspended in 0.2ml PBS. 
4. 180µl of Lysozyme digestion buffer and 20µl of Protinase K added, 
5. Incubated at 37ºC for 15 min. 
6. 400µl of Binding buffer, 5µl of control template and 20µl Protinase K added, 
Mixed well by inverting several time. 
7. Incubate at 56ºC for 15 min. 
8. Added 300µl of Ethanol and mixed well. 
9. Transferred entire sample into the PureFast spin column. Centrifuged for 1 
min. Discard the flow-through and place the column back into the same 
collection tube. 
10. Added 500µl wash buffer-1 to the PureFast spin column. Centrifuge for 30-
60 seconds and discarded the flow-through. Place the column back in to the 
same collection tube. 
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11. Added 500µl wash buffer-2 to the PureFast spin column. Centrifuge for 30-
60 seconds and discarded the flow-through. Place the column back in to the 
same collection tube. 
12. Discard the flow-through and centrifuge for an additional 1 min. This step is 
essential to avoid residual ethanol. 
13.Transferred the PureFast spin into a fresh 1.5ml micro-centrifuge tube. 
14.Added 100µl of Elution Buffer to the centre of PureFast spin column 
membrane. 
15.Incubate for 1 min at room temperature and centrifuge for 2 min. 
16.Discard the column and store the purified DNA at -20ºc. Quality and 
Quantity of extracted DNA is checked by loading in 1% agrose gel and  5µl of 
extracted DNA is used for PCR amplification. 
PCR Procedure: 
1. Reactions set up as follows: 
                                                Components Quantity 
HELINI RedDye PCR Master mix        10µl 
HELINI RedDye PCR -Primer mix         5µl 
Purified bacterial DNA         5µl 
Total volume        20µl 
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2.Mixed gently and spin down briefly 
3. place into PCR machine and program it as follows; 
 
Initial Denaturation: 95ºC for 5 min 
Denaturation           : 94ºC for 30 sec 
Annealing                : 58ºC for 30 sec                                      35 cycles 
Extension                : 72ºC for 30 sec 
Final extension   : 72ºC for 5 min 
Loading: 
1. Prepared 2% agarose gel. [ 2gm of agarose in 100ml of 1X TAE buffer] 
2. Run electrophoresis at 50V till the dye reaches three fourth distance and 
observe the bands in UV Transilluminator. 
 Agarose gel electrophoresis: 
1. Prepared 2% agarose. (2gm agarose in 100ml of 1X TAE buffer and melted 
using micro oven) 
2. When the agarose gel temperature was around 60ºC, added 5µl of Ethidium 
bromide. 
3. Poured warm agarose solution slowly into the gel platform. 
4. Kept the gel set undisturbed till the agarose solidifies. 
5. Poured 1XTAE buffer into submarine gel tank. 
6. Carefully placed the gel platform into tank. Maintained the tank buffer level 
0.5cm above then gel. 
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7. PCR samples are loaded after mixed with gel loading dye along with 10µl 
HELINI 100 bp DNA Ladder.  
[100bp, 200bp, 300bp, 400bp, 500bp, 600bp, 700bp, 800bp, 900bp, 1000bp and 
1500bp] 
8. Run electrophoresis at 50V till the dye reaches three fourth distance of the 
gel. 
9. Gel viewed in UV Transilluminator and observed the bands pattern. 
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 RESULTS 
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5.1. STUDY DESCRIPTION 
 This study was conducted at the Department of Microbiology, Tirunelveli 
Medical College, over a period of one year from April 2017 to March 2018. Out 
of 996 culture positive samples received in the Microbiology laboratory , a total 
of 100 enterococcal species were isolated. 
 These enterococcal isolates were subjected to antimicrobial susceptibility 
testing by disc diffusion method for the following antibiotics: Penicillin, 
Tetracycline, Linezolid, Ciprofloxacin, Chloramphenicol, Teicoplanin, 
Doxycycline, High level Gentamycin and Vancomycin. Susceptibility of the 
isolates to vancomycin was tested by vancomycin screen agar and E strip 
method. Those isolates found resistant to vancomycin was screened for MIC of 
Teicoplanin by E strip and Van A gene using PCR. 
5.2. STATISTICAL ANALYSIS 
 Data collected were entered in Microsoft Excel and analysed using 
statistical analysis software Statistical Package for Social Services (SPSS) v.16. 
Appropriate descriptive and inferential statistics were calculated. p values <0.05 
were statistically significant. 
5.3. ISOLATION OF ENTEROCOCCI 
 Among the 100 enterococcal isolates, 56 isolates were from male patients 
and 44 from female patients. Most of the isolates (27%) were from patients aged 
between 16 and 30 years. The mean age of the patients was found to be 35.6 
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years with a SD of 21.5 years. The age of the patients ranged from a minimum 
of 2 years to a maximum age of 84 years. The table below shows the age and 
sex distribution of the patients. 
Table 1 Age and sex distribution of the patients 
Age of the 
patients 
Sex of the patients Number of 
Enterococcal isolates 
(N=100) 
Male Female 
Less than 15 years 12 (60%) 8 (40%) 20 (20%) 
16 years to 30 
years 
13 (48%) 14 (52%) 27 (27%) 
31 years to 45 
years 
9 (45%) 11 (55%) 20 (20%) 
46 years to 60 
years 
12 (67%) 6 (33%) 18 (18%) 
More than 60 years 10 (67%) 5 (33%) 15 (15%) 
Total 56 (56%) 44 (44%) 100 
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Table 2 Distribution of isolates among Inpatients and Outpatients  
Type of patients Percentage 
Out patients 31 
Inpatients 69 
 
Out of the 100 samples, 69 samples were collected from inpatients and 
remaining 31 from outpatients.  
Figure 1 Distribution of isolates among inpatients and outpatients 
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Table 3 Distribution of the Enterococcal isolates in different clinical samples 
Sample Percentage 
Urine 93 
Sputum 4 
Pus 1 
Vaginal swab 1 
Ascitic fluid 1 
Enterococci were commonly isolated from urine (93%), followed by 
sputum (4%), ascitic fluid (1%), pus from leg ulcer (1%) and vaginal swab 
(1%). 
Figure 2 Distribution of the Enterococcal isolates in different clinical samples 
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Table 4 Distribution of Enterococcal isolates in different wards 
Ward Number of isolates  
(N=100) (%) 
Medicine 22 (22%) 
Paediatrics 21 (21%) 
Urology  17 (17%) 
Surgery 13 (13%) 
Maternity 9 (9%) 
IMCU 8 (8%) 
Nephrology 3 (3%) 
CMCHIS 2 (2%) 
Gynaecology 2 (2%) 
Thoracic 2 (2%) 
Trauma  1 (1%) 
                              Most of the urinary isolates (43%) were from Medicine and 
Pediatric ward followed by Urology ward (17%), surgery ward (13%), 
maternity ward (9%) and IMCU (8%).  
Figure  3 Distribution of Enterococcal isolates in different wards 
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Table 5 Species distribution among isolates 
Species isolated Percentage 
E.faecalis 90 
E.faecium 10 
 
The isolates were identified to be Enterococcus faecalis (90%) and 
Enterococcus faecium (10%).  
Figure  4 Species distribution among isolates 
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Table 6 Species distribution in different clinical samples 
Sample No.of Isolates E.faecalis E.faecium 
Urine 93 85 8 
Sputum 4 4 - 
Pus 1 1 - 
Ascitic fluid 1 - 1 
Vaginal swab 1 - 1 
Total 100 90 10 
                               
The above table shows the species of the Enterococcus in different 
clinical samples. All the four sputum isolates and pus isolates were found to be 
E.faecalis whereas the ascitic fluid isolate and vaginal swab isolate was found to 
be E.faecium. 
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Figure 5 Species distribution in different clinical samples 
 
  
0
20
40
60
80
100
120
140
160
180
200
Urine Sputum Pus Ascitic fluid Vaginal swab
No.of Isolates E.faecalis E.faecium
72 
 
 
5.4. ANTIBIOTIC SUSCEPTIBILITY PATTERN OF THE ISOLATES 
5.4.1. Disc diffusion method 
 The table below shows the antibiotic susceptibility pattern of the 
enterococcal isolates by Kirby bauer disc diffusion method on Mueller Hinton 
agar according to CLSI guideline Highest prevalence of resistance was observed 
against Penicillin (75%), followed by Ciprofloxacin (59%) and Vancomycin 
(48%). On the other hand, Doxycycline was found to be sensitive for 80% of 
isolates, followed by Chloramphenicol (78%) and High level Gentamicin 
(66%). 
Table 7 Antimicrobial sensitivity pattern of the Enterococcal isolates by disc 
diffusion method (N=100) 
Antibiotic Sensitive isolates (%) Resistant isolates (%) 
Penicillin 25 (25%) 75 (75%) 
Tetracycline 60 (60%) 40 (40%) 
Ciprofloxacin 41 (41%) 59 (59%) 
Chloramphenicol 78 (78%) 22 (22%) 
Doxycycline 80 (80%) 20 (20%) 
High level Gentamycin 66 (66%) 34 (34%) 
Vancomycin 52 (52%) 48 (48%) 
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 It could be seen from the below figure that only 52% of the isolates were 
sensitive Vancomycin by disc diffusion method.  
Figure 6 Antimicrobial susceptibility pattern of the isolates 
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5.4.2. Multi drug resistant isolates 
 
Table 8: Multi drug resistant isolates 
Total no of isolates 
 
MDR isolates 
100 
 
66 
 
 Out of the 100 enterococcal isolates, 66 isolates were found to be multi 
drug resistant (resistant to three or more antibiotics). 
  
Figure  7 Proportion of Multi drug resistant isolates 
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Table 9 Distribution of MDR isolates from various clinical samples 
Sample No of  isolates No. of MDR isolates 
Urine 93 59 (63.4%) 
Sputum 4 4(100 %) 
Vaginal swab 1 1(100 %) 
Ascitic fluid 1 1(100 %) 
Pus 1 1(100 %) 
Total 100 66 
 
All the four sputum isolates, isolates from vaginal swab, pus and ascitic fluid 
were found to be multidrug resistant. Almost 63% of the urine isolates were 
found to be MDR. Nearly 60% of the MDR isolates were found to be resistant 
to vancomycin by diffusion method.  
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Figure 8 Distribution of MDR isolates from various clinical samples 
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5.4.3. Vancomycin susceptibility pattern by different methods 
 Vancomycin screen agar and E strip method showed only four isolates to 
be resistant against Vancomycin. whereas, disc diffusion showed 48 isolates to 
be resistant against Vancomycin. This is depicted in the below figure.  
Table 10 Vancomycin susceptibility pattern by different methods 
Testing method 
 
% of VRE 
Disc diffusion method 
 
48 
Vancomycin screen agar 
 
4 
E strip method 
 
4 
Figure 9 Vancomycin susceptibility pattern by different methods 
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5.4.4. Vancomycin screen agar  Vs disc diffusion method 
There was a difference in the antibiotic susceptibility pattern found by 
disc diffusion method and Vancomycin screen agar 
Table 11 Antibiotic susceptibility pattern. Disc diffusion method Vs 
Vancomycin screen agar 
Disc diffusion 
method 
Vancomycin screen agar Total 
(N=100) 
Resistant 
isolates 
Sensitive 
isolates 
Resistant 
isolates 
4 (8.3%) 44 (91.7%) 48 
Sensitive isolates 0 52 (100%) 52 
Total 4 (4%) 96 (96%) 100 
 
 The above table shows that all the isolates found to be sensitive to 
vancomycin in disc diffusion method was also found to be sensitive in 
vancomycin screen agar method. However, only 8.3% of isolates found to be 
resistant to vancomycin in disc diffusion method was found to be resistant in 
vancomycin screen agar method. 
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5.4.5. E strip method Vs disc diffusion method 
 
There also exists a difference in the antibiotic susceptibility pattern found 
by disc diffusion method and E strip method. 
Table 12  Antibiotic susceptibility pattern. Disc diffusion method Vs E strip 
method 
Disc diffusion 
method 
E strip method Total 
(N=100) 
Resistant 
isolates 
Sensitive 
isolates 
Resistant 
isolates 
4 (100%) 44 (46%) 48 
Sensitive isolates 0 52 (54%) 52 
Total 4 96 100 
 
 The above table shows that all the isolates found to be sensitive to 
vancomycin in disc diffusion method was also found to be sensitive in E strip 
method. However, only 8.3% of isolates found to be resistant to vancomycin in 
disc diffusion method was found to be resistant in E strip method. All the 4 
VRE showed MIC above 16ug/ml. 
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This shows that the disc diffusion method is highly sensitive in detecting 
resistant isolates of Enterococcus (100%). But its specificity in detecting the 
resistance against Vancomycin remains low (54%).  
5.4.6. E strip method Vs Vancomycin screen agar method 
There seemed to be no difference in the antibiotic susceptibility pattern of 
the isolates found by Vancomycin screen agar and E strip method. 
     Table 13 Antibiotic susceptibility pattern. Vancomycin screen agar Vs E 
strip method 
Vancomycin 
screen agar 
E strip method Total 
(N=100) 
Resistant 
isolates 
Sensitive 
isolates 
Resistant 
isolates 
4 (100%) 0 4 
Sensitive isolates 0 96 (100%) 96 
Total 4 (4%) 96 (96%) 100 
The above table shows that all the isolates found to be sensitive to vancomycin 
in vancomycin screen agar method was also found to be sensitive in E strip 
method. Likewise, all the isolates found to be resistant to vancomycin screen 
agar method was also found to be resistant in E strip method. This shows that 
the Vancomycin screen agar method is as sensitive and as specific as E strip 
method for detecting antibiotic susceptibility of the enterococcal isolates. 
81 
 
 
5.5. PATTERN OF VANCOMYCIN RESISTANCE 
 The mean age of the patients from whom the vancomycin resistant 
enterococci were isolated was 38 years with a SD of 24.4 years. The mean age 
of the patients from whom the vancomycin sensitive strains were isolated was 
35.5 years with a SD of 21.6 years. This difference was not found to be 
statistically significant (p value – 0.82, Independent sample t test). Similarly, 
vancomycin resistance of the isolates did not find any statistically significant 
difference between males and females (p value – 0.43, 𝑥2test). The table below 
shows the pattern of vancomycin resistance among various age group and 
gender. 
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Table 14 Pattern of Vancomycin resistance among different age groups and 
gender 
Patient details Vancomycin susceptibility Total 
(N=100) 
Resistant 
isolates 
Sensitive 
isolates 
Age Less than 15 years 1 (5%) 19 (95%) 20 
16 years to 30 years 1 (3.7%) 26 (96.3%) 27 
31 years to 45 years 0 20 (100%) 20 
46 years to 60 years 2 (11.1%) 16 (88.9%) 18 
More than 60 years 0 15 (100%) 15 
Sex Male 3 (5.4%) 53 (94.6%) 56 
Female 1 (2.3%) 43 (97.7%) 44 
Outpatient 2 (6.5%) 29 (93.5%) 31 
Inpatient 2 (2.9%) 67 (97l1) 69 
Total 4 (4%) 96 (96%) 100 
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5.5.1. Vancomycin resistance pattern in different samples 
 All the four vancomycin resistant isolates were found to be from urine 
samples. Other samples which includes pus from leg ulcer, sputum, ascitic fluid 
and vaginal swab were found to be sensitive to vancomycin. However, 
statistical significance could not be drawn as there were only few sputum, pus 
and vaginal isolates as compared to urine isolates. It should also be noted that 
majority of the urine isolates (43%) were from medicine and pediatric ward. 
Figure 10  Pattern of vancomycin resistance in different clinical samples 
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5.5.2. Vancomycin resistance pattern among different Enterococcal species 
Nearly 10% of E.faecium was found to be resistant to vancomycin, 
whereas only 3% of E.faecalis was found to be resistant to vancomycin. There 
is no statistically significant difference in vancomycin susceptibility between 
the two species. 
Table No 15 pattern of Vacomycin resistance among different species 
Species Total number Vancomycin resistant 
isolates 
E.faecalis 90 3 
E.faecium 10 1 
Total 100 4 
Figure 11 Pattern of vancomycin resistance among different species 
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5.5.3. Antimicrobial susceptibility of Vancomycin resistant isolates 
Out of 100 enterococcal isolates, only four isolates were found to be 
resistant to Vancomycin by E strip method. The below chart shows the 
antimicrobial susceptibility of those vancomycin resistant enterococcal isolates. 
Table 16 Antimicrobial susceptibility of the Vancomycin resistant isolates 
Antibiotic Sensitive Resistant 
Linezolid 4 - 
Teicoplanin 2 2 
Quinipristin 4 - 
High level Gentamycin 2 2 
Penicillin - 4 
Ciprofloxacin - 4 
Doxycycline 1 3 
Figure 12 Antimicrobial susceptibility of the Vancomycin resistant isolates 
 
  All the four vancomycin resistant enterococcal isolates were also 
found to be resistant for penicillin and ciprofloxacin. Fifty percent of the 
isolates were sensitive for High level Gentamycin and Teicoplanin .All the 4 
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          Table 17  Phenotypic charecterisation of VRE  
VRE isolates n=4 MIC of 
Vancomycin by E 
strip ug/ml 
MIC of 
Teicoplanin by E 
strip ug/ml 
Phenotype 
VRE 1 >60 >16 Van A 
VRE 2 >120 >16 Van A 
VRE 3 >60 <8 Van B 
VRE 4 >60 <8 Van B 
.>=more than. < less than . 
5.6. SCREENING FOR VanA GENE 
 All the four Vancomycin resistant isolates were subjected to screening for 
VanA gene using PCR. It was found that all the four isolates were negative for 
VanA gene. 
Table 18 Screening for Van A gene by PCR 
Total VRE isolates Van A gene 
4 Negative 
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Enterococcus species have been recognised as a pathogen causing dieases like 
bacteremia, endocarditis, complicated urinary tract infections, intra abdominal 
infections, pelvic infections, wound and soft tissue infections etc. VRE has 
become an important nosocomial pathogen because of its rapid spread, high 
mortality rates associated with infections, limited option for treatment, and the 
possibility of transferring vancomycin resistance genes to other more virulent 
and more prevalent pathogens such as Staphylococcus aureus. This study was 
conducted to detect prevalence of vancomycin resistant enterococci in clinical 
isolates by phenotypic and genotypic methods.  
A total of 100 enterococcal isolates were collected from 996 culture positive 
samples received  over one year period. The majority of the isolates were from 
urine ( 93%) followed by sputum( 4%),pus (1%),ascitic fluid (1%) and vaginal 
swab (1%) In the study by V.gupta et al majority of the  isolates were from 
urine (49%) and blood (5%). 
In the study group 56 % were males and 44 % were females, Majority of the 
isolates were from the age group of 16-30 years. 69% of the study group 
consisted of inpatients and 31% were outpatients. 
90% of the isolates were identified to be E.faecalis  and 10 % was E.faecium . 
Both these species are significantly associated with clinical disease, 
Parameswarappa et at in their study have found E.faecalis to be the predominant 
isolate followed by E.faecium. Chakraborthy et al also reported E.faecalis as the 
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predominant Enterococcal species (80%-90%) in their study followed by 
E.faecium( 5%-15%).  Several species of enterococci are currently recognized, 
but generally 90% of enterococcal infections are caused by E.faecalis and 10% 
are caused by E.faecium. Although a few studies have documented an increase 
in the prevalence of E.faecium, in this study the prevalence of this species was 
considerable low. E.faecium infections has been found to be more resistant to 
penicillin and aminoglycosides which is attributed to the production of enzyme 
6-acetyl transferase and more penicillin binding proteins. 
Enterococcai are not generally regarded as high virulent bacterial pathogens, 
however, resistance to many antimicrobial drugs complicates the treatment of 
enterococcal infections. Acquired resistance to high concentrations of ampicillin 
,aminoglycoside, and glycopeptides antibiotics, specifically vancomycin, has 
exacerbated this problem. 
Antibiotic susceptibility pattern of the isolates was tested by Kirby Bauer disc 
diffusion method on Mueller Hinton agar. Highest prevalence of resistance was 
observed against  pencillin (75%) followed by ciprofloxacin (59%) and 
vancomycin (48%). Of the 100 isolates, 66 % were multiple drug resistant.. 
Both E.faecalis and E.faecium exhibited >59% resistance for ciprofloxacin in 
this study. High level of ciprofloxacin resistance has been reported by 
Anbumani et al and  Shah et al where ciprofloxacin resistance accounted for 
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58% and 62% respectvely.  The isolates in this  study showed 80% sensitivity to 
doxycycline.  
High level gentamicin resistance(HLGR) was observed in 34% of the 
enterococcal isolates in our study. This finding correlates with the Anbumani et 
al, Shah et al and Fernandez at al studies where HLGR was 56%,53% and 53% 
respectively. Studies conducted in New Delhi and Mumbai have reported 
HLGR prevalence to be as high as 70 and 100 percent ,respectively. 
In this study, the occurance of HLGR among the enterococcal isolates had no 
significant difference seen between E.faecalis and E.faecium isolates. However 
Mendiratta et al have reported greater resistance to HLG among E.faecium as 
compared to E.faecalis isolates.  
Initial screening for VRE by disc diffusion methods detected 48 isolates as 
vancomycin resistant. However MIC detection by Hicomb E strip method and 
Vancomycin screen agar method detected only 4 isolates as vancomycin 
resistant. Presumptive identification of Vancomycin resistance was done by 
Vancomycin screen agar (i.e) brain heart infusion (BHI) agar containing 6 µg 
/ml Vancomycin. 10µl of 0.5 McFarland suspension of the isolate ,along with 
positive and negative control strains, was spot inoculated onto the agar surface 
and incubated aerobically for 24hrs at 35±2ºC.Growth of > 1 colony indicated  
presumptive Vancomycin resistance.In this study 4 isolates were detected as 
VRE in Vancomycin screen agar . 
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As per CLSI guidelines the MIC of VRE is above 16µg/ml . Minimum 
inhibitory concentration (MIC) value for Vancomycin were   determined using 
Hi Comb MIC Strip (Hi-media, Mumbai). Any Enterococcus was considered 
VRE if the MIc was ≥16microgram/ml. In this study,MIC obtained for 
vancomycin by Hicomb E-test for three  resistant E.faecalis isolates were more 
than  60µg, 60µg, 120µg and the MIC obtained for the resistant  E.faecium 
isolate was above  60µg respectively .    
These findings suggest that through the disc diffusion  method is highly 
sensitive in detecting resistant isolates of Enterococcus (100%) its  specificity is 
low (54%) 
In this study the VRE isolation was 4% . Studies from Indore and Nagpur 
reported 14.29 & and  11.38% VRE ,respectively (Chitin S et al, Rahangdale 
VA et al). A study from Lucknow reported VRE in 55, 17% of isolates (Tripathi 
A et al). The prevalence of VRE varies based on geographic location, antibiotic 
use and the subject population. 
In India, the prevalence of VRE has been reported to be between 0-30 %. In our 
study,4 isolates were found to be resistant to vancomycin. Among the VRE  3 
were E.faecalis 1 was E.faecium . This is similar to the finding by Agarwal et al 
who found vancomycin resistance to be greater among E.faecalis isolates. 
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The mean age of patients from whom VRE was isolated was 38 years. All the 4 
VRE isolates were found to be from urine samples. Vancomycin resistance 
enterococci was found in 3 E.faecalis and 1 E.faecium  VRE isolates. 
All the 4 VRE isolates were found to be resistant to pencillin and ciprofloxacin . 
Of the 4 VRE isolates 2 VRE were found to be susceptible to  high level 
gentamicin. Hence, that infections could be treated with a combination of a high 
level aminoglycoside and a 𝛽 lactam antibiotic The presence of high level 
gentamycin resistance and concurrent resistance to Pencillin or Ampicillin and 
vancomycin has been reported in some studies. An USA based study 
demonstrated that gentamycin resistance plasmid might cotransfer vancomycin 
resistance plasmids. Hence the detection of high level gentamycin resistance 
along with vancomycin resistant enterococci represents a significant problem in 
this region. 
On studying the susceptibility pattern of VRE isolates to supplemental drugs 
like linezolid, Quinupristin and chloramphenicol , all of the he VRE isolates 
were susceptible to Linezolid and Quinipristin ( 100% sensitivity). 100% of the 
isolates showed resistance to chloramphenicol. The study carried out by 
V,Gupta,et al, from Chandigarh , India and MM Salem Behkit et al. from Iran 
have reported, 100% sensitivity of VRE isolates to linezolid which is similar to 
our study. Agarwal et al has also reported 100% sensitivity to linezolid in their 
study .Perlada.D.et al, from Australia also have reported 100% sensitivity to 
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linezolid and 100 % sensitivity to Chloramphenicol. But in our study 100% of 
VRE isolates were resistant  to Chloramphenicol. 
This study showed 50% of VRE isolates were sensitive to Teicoplanin. VRE 
strains have been classified by phenotypes and genotypes. Six types of 
glycopeptides resistance have been described among enterococci. Three of them 
are the most common: the VanA phenotype, with inducible high-level resistance 
to vancomycin, as well as to teicoplanin, encoded by the vanA gene; the VanB 
phenotype, with variable (moderate to high) levels of inducible resistance to 
vancomycin only, encoded by the vanB gene; and the VanC phenol type,with 
non inducible low-level resistance to vancomycin. 
The VanA and VanB phenotypes are considered the most clinically relevant and 
are usually associated with E. faecium and E. faecalis strains while the VanC 
resistance is a intrinsic characteristic of E. gallinarum (vanC1 genotype) and E. 
casseliflavus (vanC2 and vanC3 genotypes) strains (Clark et al. 1998; Huycke et 
al. 1998; Murray 1998; Cetinkaya et al. 2000).  
In this study by comparing the MIC of Vancomycin and Teicoplanin among the 
4 VRE isolates,2 were of the Van A phenotype and 2 were of the Van B 
phenotype .All the 4 VRE isolates were subjected to Van A gene screening by 
PCR. However it was found that all the four isolates negative for Van A gene. It 
could  be due to mutations in the Van A gene .Ramya Rengaraj et al have also 
noted an phenotype-genotype incongruence of Van A gene in their study and 
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suggested mutations in Van A gene as its cause. The VRE isolates in this study  
could  be harbouring other Van genes. PCR remains the gold standard for 
diagnosis of Vancomycin resistance. Emerging Vancomycin resistance among 
Enterococcus is a cause for concern as this leads to a great difficulty in treating 
serious infections caused by them. 
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  Out of  996 clinical specimens like urine, sputum,pus and Ascitic fluids 
100 Enterococcal isolates were recovered .  Majority of the specimens were 
from  inpatients (69%) then from outpatients (31%). 
 Majority of the isolates were from urine (93%) followed by sputum (4%) 
and pus (1%) ascitic fluid (1%)vaginal swab (1%). 
 A total of about 8 (8%) Enterococcal isolates were from  Intensive Medical 
care unit  and the isolation rate  from other specialities were Nephrology 
3(3%), Urology 17(17%), Surgery 13 (13%), Medicine 22 (22%) and 
Paediatrics 21 (21%). 
 Higher isolation rate   about 56% (56/100) was observed in Male patients 
when compared to Female patients 44% (44/100). 
 The age of the patients ranged from a minimum 2 years to a maximum age 
of 84 years. Most of the isolates (27%) were from patients aged between 16 
and 30 years.The mean age of the patients was found to be 35.6 years.                            
 E. Faecalis was the predominant Enterococcal species with an  isolation 
rate of about 90% in our study, followed by E.faecium   10%. 
 The antibiotic susceptibility pattern showed  highest prevalence of 
resistance against Pencillin (75%),followed by ciprofloxacin (59%) .On the 
other hand, Doxycycline was found to be sensitive for 80% of isolates 
followed by Chloramphenicol 78% and High level Gentamycin 66%. 
 
 The High level gentamicin resistance was observed in 34% of isolates.  
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 Out of 100 Enterococcal isolates,66 isolates were found to be multi drug 
resistant (resistant to three or more antibiotics). Almost 63.4% of the urine 
isolates were found to be MDR. All the 4 sputum isolates, isolates from 
vaginal swab,pus and ascitic fluid were  found to be multidrug resistant. 
 4 isolates (4%) were presumptively identified as vancomycin resistant by 
vancomycin screen agar containing 6 µg/ml vancomycin. 
 The 4 isolates found to be resistant  in vancomycin screening agar were 
also found to be  resistant  to Vancomycin by Hicomb E strip method. Of 
the 4 VRE isolates, 2 were Teicoplanin resistant by Hicomb E strip method 
 All the 4 VRE isolates were resistant to Pencillin and Ciprofloxacin. 50% 
percent of the isolates were sensitive for High level Gentamycin and 
Teicoplanin. 100% percent of the isolates were sensitive to Linezolid and 
Quinipristin. 
 2 VRE were of van A phenotype and 2 were of van B phenotype 
 All the 4 VRE as resistant isolates were subjected to detection of 
Vancomycin Resistance gene - Van A by Polymerase Chain Reaction. 
 As per the PCR results, a total of 4 isolates including 1. E.faecium and three  
E.faecalis were not  found to be of VanA Genotype. 
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Enterococci are emerging as an important pathogen causing variety of  
nosocomial infections and also cause community acquired infections 
contributing significantly to patients morbidity and mortality.  
The emergence of Vancomycin resistant Enterococci worsens the problem 
further because of the Multidrug resistance exhibited by these agents leaving 
fewer therapeutic options for the clinicians in treating the serious life 
threatening VRE infections. 
In our study we isolated a total of 100 Enterococcal isolates from various 
clinical samples with Enterococcus faecalis and Enterococcus faecium as the 
predominant species.  
Predominant species. They should Resistant to multiple antibiotics like 
penicillin, ciprofloxacin and exhibited higher rate of high level aminoglycoside 
resistance. 4 isolates were identified as vancomycin resistant enterococci by 
Vancomycin Hicomb E stip. This method can be adopted in resource limited 
settings for the detection of vancomycin resistant phenotype of Enterococci. All 
the and isolates were negative for Van A gene by PCR.  
The prevalence of VRE varies based on geographic location, antibiotic 
use of the subject population. This study emphasises the need for conducting 
frequent surveillance. Programmes for prompt identification of VRE in 
hospitals and community.  
This also highlights the need for implementation of stringent infection 
control measures like rational use of antibiotics especially restricting the use of 
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Vancomycin to minimum, proper containment and effective treatment of VRE 
infections, strict hand washing practices, education of the healthcare workers 
and other personnel involved in the patient management. These measures are to 
be strictly followed to bring down the mortality and morbidity associated with 
these hospital acquired VRE infections. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
101 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
BIBLIOGRAPHY 
102 
 
 
Anbumani et al. speciation and antimicrobial susceptibility of enterococci from a tertiary 
health care center of south india. Journal of pharmacy Research 2011;4(9).989-990 
1. Antalek, M.D., Mylotte, J.M., et al. 1995. Clinical and molecular epidemiology of 
Enterococcus faecalis bacteremia, with specialreference to strains with high-level 
resistance to gentamicin. ClinInfect Dis, 20, 103–9. 
2.  Arias.A .C, Murray B.E . Enterococcal Infections. In :Principles of Internal 
Medicine, Harrisons editor.18th ed. Mc Graw Hill Medical 
3. Agarwal J, Kalyan R, Singh M. High-level aminoglycoside resistance and β-
lactamase production in Enterococci at a tertiary care hospital in India. Jpn J Infect 
Dis 2009; 62 :158-9. 
4. Arthur, M., Depardieu, F., Cabanie, L., Reynolds, P., Courvalin, P., 
1998.Requirement of the VanY and VanX D,D-peptidases for glycopeptide resistance 
in enterococci. Mol. Microbiol. 30:819-830 
5. Boyce, J.M., Opal, S.M., et al. 1992. Emergence and nosocomial transmission of 
ampicillin-resistant enterococci. Antimicrob AgentsChemother, 36, 1032–9. 
6. Buschelman, B.J., Bale, B.J. and Jones, R.N. 1993. Species identification and 
determination of high-level aminoglycoside resistance among enterococci. 
Comparison study of sterile body fluid isolates, 1985–1991. Diagn Microbiol Infect 
Dis, 16, 119–22. 
7. Boyce, J. M., 1997. Vancomycine-resistant enterococcus: detection.             
Epidemiology and control measures. Infect. Dis. Clin. North Am.11:367-384 
8. Boyce, J. M., Mermel, L. A., Zervos, M. J., Rice, L. B., Potter-Bynoe, G.,Giorgio, C., 
and Medeiros, A. A., . 1995. Controlling vancomycineresistant enterococci. Infect. 
Control Hosp. Epidemiol. 16:634-637. 
9. Boyce, J. M., Opal, S. M., Chow, J. W., Zervos, M. J., G. Potter-Bynoe, G., Sherman, 
C. B., Romulo, R. L., Fortna, S., and A. A. Medeiros,A. A., 1994. Outbreak of multi-
drug resistant Enterococcus faecium with transferable VanB class vancomycine 
resistance. J. Clin. Microbiol. 32:1148-1153 
10. Boyd DA, Willey BM, Fawcett D, et al. Molecular characterization of Enterococcus 
faecalis NO6-0364 with low-level vancomycin resistance harboring a novel D-ala-D-
ser gene cluster,vanL. Antimicrob Agents Chemother 2008;52:2667–2672. 
11. Chitin S, Katara G, Hemvani N, Pareek S, Chitnis DS. In vitro activity of daptomycin 
& linezolid against methicillin resistant Staphylococcus aureus & vancomycin-
103 
 
 
resistant enterococci isolated from hospitalized cases in Central India.Indian J Med 
Res 2013; 137 : 191-6. 
12. Clark, N. C., Cooksey, R. C., Hill, B. C., Swenson, J. M., and Tenover, F.C., 1993. 
Characterization of glycopeptide-resistant enterococci from US hospitals. Antimicrob. 
Agent Chemother. 37:2311-2317. 
13. Clinical Laboratory Standards Institute (CLSI). Performance standards for 
antimicrobial susceptibility testing, 21stinformational supplement (M100-S21). 
Wayne, PA: CLSI;2011. 
14. Devriese, L. A., Leven, M., Goosens, H., Vandamme, P., Pot, B., Hommez, J., and 
Haesebrouck, F., 1996. Presence of vancomycinresistant enterococci in farm and pet 
animals. Antimicrob. Agents Chemother. 40:2285-2287. 
15. Dutka Malen, S., Blaimont, B., Wauters, G., and Courvalin, P., 1994. Emergence of 
high-level resistance to glycopeptides in Enterococcus gallinarum and casseliflavus. 
Antimicrob. Agents Chemother. 38:1675-1677. 
16. Eliopoulos, G. M., 1993. Increasing problems in the therapy of enterococcal             
infections. Eur. J. Clin. Microbiol. Infect. Dis. 12:409-412. 
17. Elipoulos, G. M., 1997. Vancomycin-resistant enterococci:mechanism and clinical        
relevance. Infect. Dis. Clin. North Am. 11:851-865. 
18. Facklam, R.R. and Collins, M.D. 1989. Identification of Enterococcus species isolated 
from human infections by a conventional test scheme. J Clin Microbiol, 27, 731–4. 
19. Facklam, R.R. and Elliott, J.A. 1995. Identification, classification, and clinical 
relevance of catalase-negative, gram-positive cocci, excluding the streptococci and 
enterococci. Clin Microbiol Rev, 8, 479–95. 
20. Facklam, R.R., Sahm, D.F. and Teixeira, L.M. 1999. Enterococcus. In: Murray, P.R., 
Baron, E.J., et al. (eds), Manual of clinical microbiology. Washington, DC: ASM 
Press, 297–305. 
21. Facklam, R.R., Carvalho, M.G.S. and Teixeira, L.M. 2002. History,              
taxonomy, biochemical characteristics, and antibiotic susceptibility  testing of 
enterococci. In: Gilmore, M.S., Clewell, D.B., et al. (eds),  The enterococci: 
pathogenesis, molecular biology, and antibiotic  resistance Washington, DC: ASM 
Press, 1–54. 
22. Fernandez-Guerrero ML, Goyenechea A, Verdejo C, et al. Enterococcal endocarditis 
on native and prosthetic valves: a review of clinical and prognostic factors with 
104 
 
 
emphasis on hospital-acquired infections as a major determinant of outcome. 
Medicine (Baltimore) 2007;86:363–377. 
23. Friden, T. R., Munsiff, S. S., Low, D. E., Willey, B. M., William, G.,Faur, Y., Eisner, 
W., Warren, S., and Kreiswirth, B., 1993.Emergence of vancomycine-resistant 
enterococci in New York City.Lcent. 342:76-79. 
24. Ghanem G, Hachem R, Jiang Y, et al. Outcomes for and risk factors associated with 
vancomycinresistant Enterococcus faecalis and vancomycin-resistant Enterococcus 
faecium bacteremia in cancer patients. Infect Control Hosp Epidemiol 2007;28:1054–
1059.    
25. Gilmore, M.S., Coburn, P.S., et al. 2002. Enterococcal virulence. In: Gilmore, M.S., 
Clewell, D.B., et al. (eds), The enterococci: pathogenesis, molecular biology, and 
antibiotic resistance. Washington, DC: ASM Press, 301–54. 
26. Gordon, S., Swenson, J. M., Hill, B. C., Piggot, N. E., Facklau, R. R., Cooksey, R. C., 
Thornsberry, C., Jarvis, W. R., and Tenvor, F. C. 1992. Antimicrobial susceptibility 
patterns of common and unusual species of enterococci causing infections in the 
United States. J.  Clin. Microbiol. 30:2373-2378. 
27. Gordts, B., Van Landuyt, H., Ieven, M., Vandamme, P., and Goossens, H., 1995. 
Vancomycin-resistant enterococci colonizing the intestinal tracts of hospitalized 
patients. J. Clin. Microbiol. 33:2842-2846. 
28. Guardado R, Asensi V, Torres JM, et al. Post-surgical enterococcal meningitis: 
clinical and epidemiological study of 20 cases. Scand J Infect Dis 2006;38:584–588. 
29. Harrison, T. S., Qaiyumi, S., Morris, J. G., J. r., and Schwalble, R. S., program Abstr. 
35th Intersci. Conf. Antimicrob. Agents Chemother., abstr. J. 78, 1995. 
30. Hayakawa K, Marchaim D, Palla M, et al. Epidemiology of vancomycin-resistant 
Enterococcus faecalis: a case-control study. Antimicrob Agents Chemother 
2013;57:49–55. 
31. Hancock, L.E. and Gilmore, M.S. 2000. Pathogenicity of enterococci. In:           
Fischetti, V.A. and Novick, R.P. (eds), Gram-positive pathogens.  Washington, DC: 
ASM Press, 251–8. 
32. Handwerger, S., Raucher, B., Altarac,D., Manka, J., Mrchione, S., Sing,K. V., 
Murray, B. E., wolff, J., and Walters,B., 1993. Nosocomialoutbreak due to 
Enterococcus faecium highly resistant tovancomycine, penicillin, and gentamicin. 
Clin. Infect. Dis. 16:750-755. 
105 
 
 
33. Huycke, M.M., Sahm, D.F. and Gilmore, M.S. 1998. Multiple-resistant             
enterococci: the nature of the problem and an agenda for the future. Emerg Infect Dis, 
4, 239–49. 
34. Lam, S., Singer, C., Tucci, V., Morthland, V. H., Pfaller, M. A., and Isenberg,H. D., 
1995. The challenge of vancomycine-resistant enterococci: a clinical and 
epidemiologic study. Am. J. Infect. Control. 23:170-180. 
35. Leclercq, R., Derlot, E., Duval. J., et al., 1988. Plasmid-mediated resistance to 
vancomycin and teicoplanin in E. Faceium. N Engl. J.Med. 319:157-161.  
36. Leclercq ,R., Dutka-Malen, S., Brisson-Noel, A., Molinas, C., Derlot, E., Arthur, M., 
Duval, J., Courvalin ,P., 1992. Resistance of Enterococci to aminoglycosides and 
glycopeptides. Clin. Infect. Dis. 15:495-501.Leclercq R, Courvalin, P., 1997. 
Resistance to glycopeptides in enterococci. Clin. Infect Dis. 24:545-554 
37. Livornese, L. L., Dias, S., Samel, C., Romanowski, B., Taylor, S., May,P., Pitsakis, 
P., Woods, G., Kaye, D., and Levison, M. E., 1992.Hospital-acquired infection with 
vancomycin-resistant Enterococcusfaecium transmitted by electronic thermometers. 
Ann. Intern. Med.117:112-116. 
38. armarkar MG, Gershom ES, Mehta PR. Enterococcal infections with special reference 
to phenotypic characterization & drug resistance. Indian J Med Res 2004;119 (Suppl): 
22-5. 
39. Karanfil, L. V., Murphy, M., Josephson, A., Gaynes, R., Mandel, Hill, B.C., and 
Swenson, J. M., 1992. Acluster of vancomycine-resistant Enterococcus faecium in an 
intensive care unit. Infect. Control Hosp. Epidemiol. 13:195-200 
40. Klare, I., Heier, H., Claus, H., Bohme, G., Marin, S., Seltmann, G.,             
Hakenbeck, R., Antanassova, V., and Witte, W., 1995. E. faecium strains with vanA-
mediated high-level glycopeptide resistance isolated from animals foodstuffs and 
fecal samples of humans in the community. Microb. Drug Resist. 1:265-272. 
41. Klare, I., Heier, H., Claus, H., and Witte, W., 1993. Environmental strains  of 
Enterococcus faecium strains with inducible high-level resistance to glycopeptides. 
FEMS Microbiol. Lett. 106:23-29. 
42. Klare, I., Heier, H., Claus, H., Bohme, G., Marin, S., Seltmann. G., Hakenbeck, 
R.,Santanassova, V., and Witte,W., 1995. Enterococcus faecium strains with VanA-
mediated high-level glycopeptide resistance isolated from food stuffs and fecal 
samples of humans in  the community. Microb. Drug Resist. 1:265-272. 
106 
 
 
43. Klare, I., Heier, H., Claus, H., Reissbroadt, R., and Witte,W., 1995. VanA-mediated 
high-level glycopeptide resistance in E. faecium strains from animal husbandry. 
FEMS Microbiol. Lett. 125:165-172. 
44. Knoll BM, Hellman M, Kotton CN. Vanomycin-resistant Enterococcus faecium 
meningitis in adults: case series and review of the literature. Scand J Infect Dis 
2013;45:131–139. 
45. Karmarker MG Gershom ES et al. enterococcal infection with special reference to phenotypic 
characterization and drug resistance.Indian J Med Res 2009;119:22-5 
46. Mayhall, C. Glen., “Prevention and Control of Vancomycin McDonald, L. C., 
Kuehnert, M. J., Tenover, F. C., and Jarvis, W. J., 1997. Vancomycin-resistant 
enterococci outside the health-care setting: prevalence, sources, and public health 
implications. Emerg. Infect. Dis. 3:311-317. 
47. Mato, R., delancestre, H., Carraher, M., Roberts, R. B., and Tomasz, A.,1996. 
Multiplicity of genetic backgrounds among vancomycineresistantEntrococcus 
faecium isolates recoverd from an outbreak in a New York City Hospital. Microb. 
Drug Resist. 2:309-317. 
48. Mendiratta DK, Kaur H, Deotale V, Thamke DC, NarangR, Narang P. Status of high 
level aminoglycoside resistan    in Enterococcus faecium and Enterococcus faecalis in   
hospital of central India. Indian J Med Microbiol 2008; 26 :369-71. 
49. Murray BE. The life and times of the Enterococcus. Clin Microbial  Rev 1990; 3:46-
65. Back to cited text no.1  
50. Murray, B. E., 1995. Editorial response, Clin. Infect. Dis. 20:1134-1136. 
51. Murray, B. E., 1997. Vancomycin-resistant enterococci. Am. J. Med. 101:284-293. 
52. Moellering, R.C. Jr 1992. Emergence of Enterococcus as a significant             
pathogen. Clin Infect Dis, 14, 1173–8. 
53. Mondino, S.S.B., Castro, A.C.D., et al. 2003. Phenotypic and genotypic            
characterization of clinical and intestinal enterococci isolated from inpatients and 
outpatients in two Brazilian hospitals. Microb Drug Res, 9, 2, 167–74. 
54. Navarro, F., Courvalin, P., 1994. Analysis of genes encoding D- alanine-D-alanine 
ligase-related enzymes in Enterococcus casseliflavus andEnterococcus flavescens. 
Antimicrob Agents Chemother. 38:1788-1793. 
55. Noble, C.J. 1978. Carriage of group D streptococci in the human bowel. J Clin Pathol, 
31, 1182–6. 
107 
 
 
56. Ostrowsky, B. E., Clark, N. C., Thuvin-Eliopoulos, C., Venkataraman, L., Samore, M. 
H., Tenover, F. C., Eliopoulos, G. M., Moellering, R.C., j. r., and Gold, H. S., 1999. A 
cluster of VanD vancomycinresistantEnterococcus faecium: molecular 
characterization and clinical epidemiology. J. Infect. Dis. 180:1177-1185. 
57. Parvathi S, Appalaraju  B. Isolation, characterisation and antibiogram of Enterococci 
from clinical samples. Indian J pathol Microbial 2003;46:501-3 Back to cited text 
no.2 
58. Perichon, B., Reynolds, P., Courvalin, P., 1997. VanD-typeglycopeptide-resistant 
Enterococcus faecalis BM4339. Antimicrob Agents Chemother. 41:2016-2018 
59. Pintado V, Cabellos C, Moreno S, et al. Enterococcal meningitis: a clinical study of 
39 cases and review of the literature. Medicine (Baltimore) 2003;82:346–364. 
60. Quintiliani, R., J. r., and Courvalin, P., 1994. Conjugal transfer of the vancomycin 
resistance determinant vanB between enterococci involves the movement of large 
genetic elements from chromosome to chromosome. FEMS Microbiol. Lett. 119:359-
364. 
61. Quintiliani, R., J. r., Evers, S., and Courvalin, P., 1993. The vanB gene cofers various 
levels of self-transferable resistance to vancomycin enterococci. J. Infect. Dis. 
167:1220-1223.resistance in Gram-Positive Coccal Microorganisms: Fire Prevention 
and Fire Fighting.” 
62. Rahangdale VA, Agrawal G, Jalgaonkar SV. Study of antimicrobial resistance in 
enterococci. Indian J MedMicrobiol 2008; 26 : 285-7. 
63. Ross PW. Streptococcus and enterococcus. In colle JG, Fraser BP, Marimion BP, et 
al., editors. Mackie and McCartney practical Medical Microbiology. 14TH  ed. 
London: churchill Livingstone; 1996.p. 263-74. Back to cited text no 4. 
64. Sahm, D.F. and Torres, C. 1988. High-content aminoglycoside disks for determining 
aminoglyside-penicillin synergy against Enterococcusfaecalis. J Clin Microbiol, 26, 
257–60. 
 
 
65. Schaberg, D.R., Culver, D.H. and Gaynes, R.P. 1991. Major trends   in the microbial 
etiology of nosocomial infection. Am J Med, 91,79S–82S. 
66. Shah et al. prevalence of enterococci with higher resistance level in a tertiary care 
hospital: a matter of concern. national journal of medical research. Volume 2 Issue 1 Jan 
– March 2012 ;25-27  
108 
 
 
67. Schleifer, K.H. and Kilpper-Balz, R. 1984. Transfer of Streptococcus faecalis and 
Streptococcus faecium to the genus Enterococcus nom. rev. as Enterococcus faecalis 
comb. nov. and Enterococcus faecium comb. nov. Int J Syst Bacteriol, 34, 31–4. 
68. Schleifer, K.H. and Kilpper-Balz, R. 1987. Molecular and  chemotaxonomic 
approaches to the classification of streptococci,  enterococci and lactococci: a review. 
Syst Appl Microbiol, 10, 1–19. 
69. Smith, T. H. A. W. S., Mair, M. E., Sharp., and Halt, j. g., 1986. Bergys Manual of 
syst. Bacteriol.8 edition. Willian and Walkins, London, U. K. Spiegel, C. A., 1988. 
Laboratory detection of high-level aminoglycosideaminocyclitol resistance in 
Enterococcus spp. J. Clin. Microbiol.26:2270-2274. 
70. Satake, S., Clark, N., Rimland, D., Nolte, F. S., And Tenover, F. C.,1997. Detection 
of vancomycin-resistant enterococci in fecal samples by PCR. J. Clin. Microbiol. 
35:2325-2330. 
71. Swenson, J. M., Ferraro, M. J., Sahm, D. F., P, Charache, and Tenover, F. C., 1992. 
New vancomycine disk diffusion breakpoints forenterococci. The National 
Committee for Clinical Laboratory Standards Working Group on Enterococci. J. Clin. 
Microbiol. 30:2525-2528. 
72. Swenson, J.M., Ferraro, M.J., National Committee for ClinicalLaboratory Standard 
Working Group on Enterococci, et al. 1995.Multilaboratory evaluation of screening 
methods for detection of highlevelaminoglycoside resistance in enterococci. J Clin 
Microbiol, 33,3008–18. 
73. Sood s, Malhotra M, Das BK, Kapil A. Enterococcal infections & antimicrobial 
resistance.  Indian Med Res 2008;128:111-21. Back to cited text no.3  
74. Strausbaugh, L.J. and Gilmore, M.S. 2000. Enterococcal infections. In:Stevens, D.L. 
and Kaplan, E.L. (eds), Streptococcal infections: clinicalaspects, microbiology, and 
molecular pathogenesis. New York: Oxford University Press, 280–301. 
 
75. Stern, C.S., Carvalho, M.G.S. and Teixeira, L.M. 1994. Characterization of 
enterococci isolated from human and nonhuman sources in Brazil. Diagn Microbiol 
Infect Dis, 20, 61–7. 
76. Tannock, G.W. and Cook, G. 2002. Enterococci as members of the intestinal 
microflora of humans. In: Gilmore, M.S., Clewell, D.B., et al. (eds), The enterococci: 
pathogenesis, molecular biology, and antibiotic resistance. Washington, DC: ASM 
Press, 101–32. 
109 
 
 
77. Teixeira, L.M., Facklam, R.R., et al. 1995. Correlation between phenotypic 
characteristics and DNA relatedness with Enterococcus faecium strains. J Clin 
Microbiol, 33, 1520–3. 
78. Tripathi A, Shukla SK, Singh A, Prasad KN. A new approach of real time polymerase 
chain reaction in detection of vancomycin-resistant enterococci and its comparison 
with other methods. Indian J Med Microbiol 2013; 31 : 47-52. 
79. Tornieporth, N. G., Roberts, R. B., John, J., Hafnier, A., and Riley, L. W.,1996. Risk 
factors associated with vancomycin-resistant, Enterococcus faecium infection or 
colonization in 145 matched case patients and control patients. Clin. Infect. Dis. 
23:765-772. 
80. Tyrrell, G.J., Turnbull, L., et al. 2002. Enterococcus gilvus sp. nov. and              
Enterococcus pallens sp. nov. isolated from human clinical specimens. J Clin 
Microbiol, 40, 1140–5. 
81. V. Gupta,Singla. N,et al,Speciation and antimicrobial  susceptibility pattern of 
Enterococci from tertary heath care centre in north India,J Clin Diag Res2007;1: (5) 
,32-5. 
82. Walsh, Christopher., 2001. “Molecular Mechanisms that confer antibacterial drug 
resistance.” Nature17 Aug. 406: 775-781. 113.Wegener, H. C., Madsen, M., Nielsen, 
N., and Aarestrup, F. M., 1997. Isolation of vancomycin resistant enterococcus 
faecium from food. Int. J. Food Microbiol. 35:57-66 
83. Woodford, N., Johnson, A. P., and Morrison, D., 1995. Current perspectives on 
glycopeptide resistance. Clin. Microbial. Rev. 8:585-61 
84. Xu X, Lin D, Yan G, et al. vanM, a new glycopeptide resistance gene cluster found in 
Enterococcus faecium. Antimicrob Agents Chemother 2010;54:4643–4647. 
85. Zarrilli R, Tripodi MF, Di Popolo A, Fortunato R, Bagattini M, Crispino M, et al. 
Molecular epidemiology of high-level aminoglycoside-resistant enterococci isolated 
from patients in a university hospital in southern Italy. J Antimicrob Chemother 2005; 
56:827-35.   
 
 
 
 
110 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
Appendix  
111 
 
 
CLINICAL PROFORMA 
PROFORMA 
Name :                                                                           IP No.: 
Age :       
Sex : 
Address : 
 
Investigation 
Lab. No. : 
Gram Stain : 
Catalase : 
Culture Plate findings : 
i) Mac Conkey Agar- 
ii) 5% Sheep Blood Agar- 
Phenotypic Identification : 
i) Bile Esculin Hydrolysis-  
ii) Growth on 6.5 % NaCl- 
iii) Heat Tolerance (60 º C for 30 minutes) 
iv) Arginine Hydrolysis  
Antibiotic Susceptibilty  
Penicillin G (10 µg)- S/R  ;  Ciprofloxacin (5 µg)- S/R ;            
Chloramphenicol( 30 µg) – S/R ; Tetracycline (30µg ) – S/R 
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Doxycycline(30 µg)- S/R  ; Vancomycin (30µg) – S/R 
Teicoplanin( 30µg) – S/R ; Linezolid(30µg ) – S/R 
High Level Gentamicin (120µg) – S/R 
Vancomycin Screen Agar-  
E strip –  
i) MIC of Vancomycin 
ii) Mic of Teicoplanin 
PCR for vanA gene 
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MEDIA PREPARATION 
 
Blood agar: 
Ingredients 
Sterile sheep blood -5 ml 
Nutrient agar -100 ml 
Autoclave the nutrient agar base at 121º C for 15 minutes. Cool 
to 45-50º C and add blood with sterile precautions and pour into Petri 
dish plates. 
 
MacConkey Agar 
Ingredients Grams/litre 
Peptic digest of animal tissue - 17 
Proteose peptone - 3 
Lactose - 10 
Bile salts - 1.5 
Sodium chloride - 5 
Neutral red - 0.03 
Agar -15 
Final pH at (25º C) 7.1±0.2. 
Suspend 51.53 grams in 1000 ml of distilled water. Heat to 
boiling to dissolve the medium completely. Sterilize by autoclaving at 
15 lbs pressure (121ºC) for 15 minutes. Mix well and pour into petri dish 
plates. 
 
Mueller Hinton Agar: 
Ingredients 
Beef infusion - 300 g/l 
Casein acid hydrolysate - 17.50 g/l 
Starch -1.50 g/l 
Agar -17.00 g/l 
Final pH at 25º C 7.4. 
Suspend 38 gms in 1000 ml of distilled water. Heat to boiling to 
dissolve the medium completely. Sterilize by autoclaving at 15 lbs 
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pressure (121ºC) for 15 minutes. Mix well and pour 20-25 ml of it into 
petri dishes of 90 mm diameter to a depth of 4 mm of medium. 
 
Bile Esculin Agar: 
Ingredients : 
Peptone - 5 gm 
Beef extract -3gm 
Oxgall(bile) -40gm 
Esculin -1gm 
Ferric citrate -0.5gm 
Agar -15gm 
Distilled water -1 L 
pH 7.0 
heat to dissolve the contents completely, sterilize at autoclave at 121ºC 
for10 minutes, pour into slants/ petri plates. 
 
6.5% NaCl broth: 
Nutrient broth - 1L 
NaCl - 6.5gm 
Dissolve the contents completely , autoclave at 121ºc for15 min and 
distribute in tubes. 
 
Brain -Heart infusion agar: 
Ingredients : 
Agar - 15gm 
Bran heart infusion broth -1L 
pH 7.4 
Dissolve the agar completely by boiling . autoclave at 121ºc for 15 min. 
cool to about 50ºC and pour into petri dish plates. 
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Vancomycin Screen agar: 
Ingredients : 
Agar - 15gm 
Brain heart infusion broth - 1 L 
Vancomycin - 6mg/L 
Prepare Brain heart infusion agar as described above , cool to 50ºC and 
Add Vancomycin 6µg/ml , mix well and pour into petri dish plates. 
 
Cation Adjusted Mueller –Hinton broth: ( MHA broth 2) ( Himedia 
lab). 
Cation adjusted Mueller- Hinton broth base - 21 gm 
Distilled water -1L 
Dissolve the contents by boiling and sterilize by autoclaving at 121ºC 
for 15 min 
 
 
TABLE. 1.ZONE DIAMETER INTERPETIVE STANDARDS FOR 
ENTEROCOCCUS SPP. 
 
Antimicrobial 
agent 
Disk content Zone diameter 
R IM R 
Penicillin G 10 units ≤14 - ≥15 
Ciprofloxacin 5µg ≤16 16-20 ≥17 
Doxycycline 30µg ≤12 13-15 ≥16 
HLS-high level 
gentamicin 
120µg 6 7-9 ≥10 
Vancomycin 30µg ≤14 15-16 ≥17 
Teicoplanin 30µg ≤10 11-13 ≥14 
Chloramphenicol 30µg ≤12 - ≥18 
Linezolid 30µg ≤20 - ≥23 
Quinupristin 15µg ≤15 16-18 ≥19 
Tetracycline 30µg ≤14 15-18 ≥19 
R-resistant, IM-intermediate S-sensitive 
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                                       Table 2  E-Strip MIC Interpretive standards  
ANTIMICROBIAL AGENT E strip MIC level in µg 
 S I R 
Vancomycin ≤4 8-16 ≥32 
Teicoplanin ≤8 16-32 ≥32 
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Gram Stain showing Enterococcus faecalis on Mac Conkey Agar 
 
Showing colony of Enterococcus faecalis on Mac Conkey Agar 
 
COLOUR PLATES 
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BILE – ESCULIN POSITIVE ISOLATES 
 
BILE ESCULIN    5% SHEEP BLOOD AGAR SHOWING NON-      
                                                                           HAEMOLYTIC COLONY 
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Vancomycin Screen Agar  
 
ANTIBIOTIC SUSCEPTIBILITY PATTERN OF ENTEROCOCCUS FAECALIS 
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Vancomycin E Strip 
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Polymerase Chain reaction with Van A Gene  
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1 24 Female IP Urology UTI Urine E.Fecalis S S S S R S S S S Negative S   - 
2 21 Female IP CMCHIS Fever Urine E.Fecalis S S S S S S S S S Negative S   - 
3 45 Male IP Medicine UTI Urine E.Fecalis S S S S R R R S S Negative S   - 
4 42 Female IP Urology PUO Urine E.Fecalis S S S S S S S S s Negative S   - 
5 11 MCH IP Medicine UTI Urine E.Fecalis R S S S R S R S S Negative S   - 
6 24 Male IP Medicine UTI Urine E.Fecalis R S S s R R S S R Negative S   - 
7 65 Male IP Pediatric Fever Urine E.Fecalis R S R S S S S S S Negative S   - 
8 2 MCH IP Pediatric Fever Urine E.Fecalis R S R S S S S S S Negative S   - 
9 25 Male IP Urology UTI Urine 
E.Faeciu
m R S S R R R S R S Negative S   
- 
10 5 Male IP Pediatric Fever Urine E.Fecalis R S S R S R S S S Negative S   - 
11 25 Male IP Urology UTI Urine E.Fecalis R S S S R s R S R Negative S   - 
12 52 Male IP Medicine UTI Urine E.Fecalis R S S S S R S S R Negative S   - 
13 62 Male IP Surgery UTI Urine E.Fecalis R S R S R S S S R Negative S   - 
14 37 Female IP Labour  POSTLSCS Urine E.Fecalis R R S S R R R S R Negative S   - 
15 65 Female IP Thoracic URI Sputum E.Fecalis S R S S R S R S R Negative S   - 
16 24 Female IP Labour  PID 
vaginal 
swab 
E.Faeciu
m S S R S R S R S R Negative S   
- 
17 16 Male IP Medicine URI Sputum E.Fecalis S R S R S R R S R Negative S   - 
18 26 Female IP Thoracic LRI Sputum E.Fecalis R S R S R S R S R Negative S   - 
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19 56 Female IP Gynec URI Sputum E.Fecalis R S R S R S R S R Negative S   - 
20 5 MCH IP Pediatric UTI Urine E.Fecalis S S S S R S S S S Negative S   - 
21 70 Male IP Urology UTI Urine E.Fecalis S S S S R S S S R Negative S   - 
22 5 FCH OP Pediatric Fever Urine E.Fecalis S S S S R S S S R Negative S   - 
23 6342 Female IP Labour  UTI Urine E.Fecalis S S S S R S S S R Negative S   - 
24 65 Male IP Trama   Urine E.Fecalis R R S S R R R S R Negative S   - 
25 58 Male IP Urology UTI Urine 
E.Faeciu
m R S R S R R R R R Positive R R  
Negativ
e 
26 60 Male Op Surgery UTI Urine E.Fecalis R S S R R S S R R Negative S   - 
27 35 Male IP Surgery UTI Urine E.Fecalis R R R S S S S S R Negative S   - 
28 57 Male Op Surgery UTI Urine E.Fecalis R R R S R R S R R Positive R R  
Negativ
e 
29 3139 FCH IP Pediatric Fever Urine E.Fecalis R S R S R S R S R Negative S   - 
30 84 Male Op Urology UTI Urine E.Fecalis S R S S R S R R R Negative S   - 
31 10 MCH Op Pediatric UTI Urine E.Fecalis R R R R S R S R R Negative S   - 
32 55 Female IP IMCU CKD Urine E.Fecalis S S S S S S R R R Negative S   - 
33 7 MCH OP Pediatric Fever Urine E.Fecalis R R R R R S R S S Negative S   - 
34 45 Male IP Urology UTI Urine E.Fecalis R R R R R S R S S Negative S   - 
35 21 Female IP Labour  Fever Urine E.Fecalis R S R S S S S S S Negative S   - 
36 5 MCH IP Pediatric Fever Urine E.Fecalis R R S S R S R S S Negative S   - 
37 25 Male IP Urology UTI Urine 
E.Faeciu
m R S S S R S S S S Negative S   
- 
38 2 FCH IP Pediatric Fever Urine E.Fecalis S R S S S S S S S Negative S   - 
39 65 Male IP Medicine UTI Urine E.Fecalis R R S S S S S S S Negative S   - 
40 24 Male IP Medicine UTI Urine E.Fecalis R R S S R S S S S Negative S   - 
41 11 MCH IP Pediatric Fever Urine E.Fecalis R S R R R S R R R Negative S   - 
42 62 Male IP Surgery UTI Urine E.Fecalis R S S R S S R R R Negative S   - 
43 42 Female IP Surgery UTI Urine E.Fecalis R S S R R S R S S Negative S   - 
44 45 Male IP Medicine UTI Urine E.Fecalis R S S R R S R R R Negative S   - 
45 21 Female IP CMCHIS UTI Urine E.Fecalis R R S R R S R R R Negative S   - 
46 24 Female IP Urology UTI Urine E.Fecalis S R S S R S S S S Negative S   - 
47 54 Male IP Pediatric Fever Urine E.Fecalis R S R S R S S S S Negative S   - 
48 49 Male IP Medicine UTI Urine E.Fecalis S S R R S S S S S Negative S   - 
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49 55 Female IP IMCU   Urine E.Fecalis S   R R S S S S S Negative S   - 
50 76 Female IP Medicine UTI Urine 
E.Faeciu
m R   R R R S R R R Negative S   
- 
51 43 Male IP IMCU UTI Urine E.Fecalis R R R R R R R R S Negative S   - 
52 60 Female Op Surgery UTI Urine E.Fecalis R   S S         S Negative S   - 
53 58 Male Op Medicine UTI Urine E.Fecalis R R R R S S R R R Negative S   - 
54 35 Female Op Labour   UTI Urine E.Fecalis S S S S S S S S S Negative S   - 
55 73 Male IP IMCU PUD-Fever Urine E.Fecalis S S R R S S S S S Negative S   - 
56 6 MCH OP Pediatric Fever Urine E.Fecalis R R R R S S S S R Negative S   - 
57 18 Male IP IMCU Epilepsy Urine E.Fecalis S S R S R S S S S Negative S   - 
58 28 Female IP Labour  LSCS-POD Urine 
E.Faeciu
m S S R S R S S S S Negative S   
- 
59 25 Male OP Medicine UTI Urine E.Fecalis S S S S S S S S S Negative S   - 
60 21 Female OP Labour  UTI Urine E.Fecalis R R S R S S R S S Negative S   - 
61 4 FCH OP Pediatric UTI Urine E.Fecalis R R R S R S R S R Negative S   - 
62 8 MCH OP Pediatric Fever Urine E.Fecalis S S S S S S S S S Negative S   - 
63 37 Female OP Medicine UTI Urine E.Fecalis R R R S S S S S R Negative S   - 
64 36 Female OP Gynec PID Urine E.Fecalis R S S S R S S S R Negative S   - 
65 38 Male IP Nephro CKD Urine E.Fecalis R S R R S S S S S Negative S   - 
66 47 Female IP Surgery Ulcerleg Pus E.Fecalis R S R R R S S S S Negative S   - 
67 39 Female OP Urology UTI Urine E.Fecalis R S S S S S S S S Negative S   - 
68 55 Female IP Surgery   
Ascitic 
Fluid 
E.Faeciu
m R R R R R S S S S Negative S   
- 
69 2 FCH IP Pediatric PUO Urine E.Fecalis R                 Negative S   - 
70 65 Male IP Medicine PUO Urine E.Fecalis R S S S S S S S S Negative S   - 
71 37 Male IP IMCU CKD Urine E.Fecalis R S R S S S S S S Negative S   - 
72 7 FCH IP Pediatric PUO Urine E.Fecalis R R R R R R R S S Positive R S 
Negativ
e 
73 60 Male IP IMCU  UTI Urine E.Fecalis R s S R S S S S S Negative S   - 
74 33 Female IP Medicine UTI Urine E.Fecalis R R R R R R R S S Negative S   - 
75 21 Male IP Surgery PUO Urine E.Fecalis R S R S S R S S S Negative S   - 
76 55 Male OP Medicine UTI Urine E.Fecalis R R R R R S R S S Negative S   - 
77 28 Female OP Urology UTI Urine E.Fecalis R S R R R R R S S Negative S   - 
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78 19 Male IP IMCU CKD Urine E.Fecalis R S S R S S S S S Negative S   - 
79 55 Male OP Urology UTI Urine E.Fecalis R R R R R R R S S Negative S   - 
80 28 Female OP Medicine Fever Urine 
E.Faeciu
m R S S S S S S S S Negative S   
- 
81 79 Male IP Medicine UTI Urine E.Fecalis S R S R S S S S S Negative S   - 
82 35 Female OP Urology UTI Urine E.Fecalis R R R R S S S S S Negative S   - 
83 4 FCH IP Pediatric PUO Urine E.Fecalis S S S R S S S S S Negative S   - 
84 11 FCH IP Pediatric PUO Urine E.Fecalis R S S S S S S S S Negative S   - 
85 80 Female IP Medicine UTI Urine E.Fecalis R R R S R S R S S Negative S   - 
86 32 Male OP Urology UTI Urine E.Fecalis R S S R S S S S S Negative S   - 
87 8 FCH IP Pediatric PUO Urine E.Fecalis R S S R R S R S S Negative S   - 
88 47 Male IP Medicine PUO Urine E.Fecalis R R R R R S R S S Negative S   - 
89 30 Male OP Surgery     E.Fecalis R R R R R R S R S Positive R S 
Negativ
e 
90 21 Male OP Urology UTI Urine E.Fecalis R S S R R S R S S Negative S   - 
91 28 Female IP Obestetric UTI Urine 
E.Faeciu
m R R R S R S R S S Negative S   
- 
92 30 Male OP 
Nephrolog
y UTI Urine E.Fecalis R S S R S R S R R Negative S   
- 
93 4 MCH IP Medicine PUO Urine E.Fecalis R S S R R S R S S Negative S   - 
94 27 Female OP Surgery UTI Urine E.Fecalis R R R R R S R S S Negative S   - 
95 42 Male IP Medicine DM Urine E.Fecalis R S R S R R S R S Negative S   - 
96 62 Female IP Surgery PUO Urine E.Fecalis R S S R S S S S S Negative S   - 
97 52 Male OP 
Nephrolog
y CKD Urine E.Fecalis R R R R S R S R S Negative S   
- 
98 39 Female OP Urology UTI Urine E.Fecalis R S S S S S S S S Negative S   - 
99 12 MCH OP Pediatric Fever Urine E.Fecalis R R R R R S R S S Negative S   - 
100 22 Female OP Labour  UTI Urine 
E.Faeciu
m R S R S R S S R S Negative S   
- 
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ABBREVIATIONS: 
 
ATCC – American Type Culture Collection 
CLSI- Clinical Laboratory Standard Institute 
MDR- Multi Drug Resistance 
IP-Inpatient 
M-Male patient 
F-Female patient 
Mch-Male child 
Fch-Female child 
UTI- Urinary tract infection 
S- Susceptible R-Resistant 
vanA – van A genotype VRE 
VRE- vancomycin resistant Enterococci 
HLG –High Level Gentamicin 
MIC – Minimum Inhibitory Concentration 
 
